Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Peregrine Pharmaceuticals (PPHM)

Add PPHM Price Alert      Hide Sticky   Hide Intro
Moderator: TekNuLoof, cheynew, cjgaddy, north40000, Couch , 4OurRetirement
Search This Board: 
Last Post: 6/29/2017 6:00:02 AM - Followers: 837 - Board type: Free - Posts Today: 10

Peregrine Pharmaceuticals, Inc. (PPHM), Tustin CA. is committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development & mfg. organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP mfg. & dev. capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. ( ), which provides development & biomfg. services for both Peregrine & 3rd-party customers. The company is also working to evaluate its lead immunotherapy candidate, BAVITUXIMAB, in combination with immune stimulating therapies for the treatment of various cancers, and developing its PROPRIETARY EXOSOME TECHNOLOGY for the detection & monitoring of cancer using assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample.

Bavituximab, a phosphatidylserine(PS)-targeting antibody, represents a new approach to treating cancer (3:34 video).
...Bavituximab was invented by UTSW's Dr. Philip Thorpe (1951-2013), and research continues in Dr. Rolf Brekken's UTSW lab.
BAVI MOA: By blocking the immunosuppressive signal of exposed PS, Bavi mediates multiple immunostimulatory changes in the tumor environment, including a reduction of tumor-promoting immune cells and an increase in tumor fighting (M1) macrophages, dendritic cells, and cytotoxic T-cells (CD8+ CD45+ CD3+) that fight solid tumors. (see: AACR'15 & ASCO'15 & ImVacS’15 & SITC'15 & S.King/1-18-16 & AACR'16 & AACR'17 & ASCO'17)
COLLABS: In addition to the ongoing UTSW/Brekken/Schroit research collab., Peregrine began working w/Mem-Sloan-Kettering(Jedd Wolchok Lab) in Jul'15(2 known studies a/o 4-2017: #1/Bavi+PD1+Rad, #2/Bavi+”ACT) to investigate “Novel PS-Targeting Immunotherapy Combos”, then w/AstraZeneca in Aug'15(see PR) to run human trials evaluating Bavi+Durvalumab(Imfinzi) in "mult-solid-tumor-types", and w/The Natl. Comprehensive Cancer Network (NCCN) in Jan'16 via a $2M res. grant to NCCN which will “significantly expand Peregrine's clinical evaluation of bavituximab” at “27 of the world's leading cancer centers” (9-16-16: NCCN selects 3 Bavi Trials to beg. early'17 at Moffitt/MassGen/JohnsHopkins). Also, w/Duke Univ. (See Dr. Herbert K. Lyerly: AACR-IO/10-22-16), MD Anderson (See Dr. Jason Fleming),  Rutgers Univ. (See Dr. Raymond Birge), and ImmunoVaccine Inc. (AACR'17 4-4-17 #3657). MORE on PreClin. Collabs:
AVID: Peregrine also operates Avid Bioservices, a wholly owned cGMP CMO subsidiary, which provides contract mfg. services on a fee-for-service basis (revs. May'06-Jan'17=$213.3mm), as well as support of Peregrine's own product pipeline.
5-2017: Avid II(Myford) expands; total Avid mfg. capacity now > 11,000L - see
...??Cancer Moonshot 2020 – see S.King's 1-14-16 EP-Vantage comments:
...??4-13-16: Sean Parker Donates $250mm to Launch Cancer Immunotherapy Inst. (6 key centers: MSKCC Stanford UCLA UCSF MDA UPenn). Dr. Jedd Wolchok says, "This new institute is paradigm shifting."

4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)  
"Phil will be sorely missed as a colleague and friend. At Peregrine, each of us is pursuing Phil's dream of bringing important drugs to patients who need them based on his basic research. We are more motivated than ever to see this dream through."
…Dr. Thorpe’s successor at UTSW: long-time colleague, co-inventor of 2C3, Dr. Rolf A. Brekken, PhD -

8-2014: UK colleagues from Chester Beatty Labs(ICR/Univ-London), ICRF(IsraelCancerRes), & UTSW create memorial for Dr.Thorpe in London’s Chelsea Physic Garden:

Yahoo Quote & Profile for PPHM: ...Nasdaq Quote: ...PPHM Tweets:
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401, Tim Brons (Media) 415-675-7402


Apr1-5/Booth3312: AACR 2017, WashDC (5 posters, incl. new 2nd MSKCC/Wolchok Bavi+ACT study) - poster images:
...MSKCC+PPHM: 4-2-17/1pm #574, “PSTargeting+RAD+AntiPD1 Promotes Anti-Tumor Activity, Melanoma”
...MSKCC+PPHM: 4-3-17/8am #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma” SEE:
...PPHM: 4-4-17/8am #3652, “PSTargeting+LAG3+AntiPD1 Significantly Enhances Anti-Tumor Activity, Triple- MBC”
...IMMUNOVACCINE+PPHM: 4-4-17/8am #3657, ”PSTargeting Enhances Anti-Tumor Activity of a Tumor Vaccine(DepoVax), HPV-Induced Tumor”

...SUNRISE BIOMARKER #3: 4-3-17/1pm #CT159/25, “
y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker." SEE:
May18-21: ICHC’17, 15th Intl. Congress of Histo/Cyto Chemistry - from Molecules to Diseases, Turkey
...May19 12pm: Raymond Birge (Rutgers), “Phosphatidylserine Sensing by TAM Receptors Regulates AKT-dependent Chemo-Resistance & PD-L1 Expression”
Jun2-6: ASCO 2017, Chicago (PPHM Booth #13124, next to Moffitt) - 6-5-17 PR & poster image:
...6-3-17 1:15-4:45pm, #11603, “Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study [Biomarker #4]”, Senior Author: Clifford Hoyt, "Technology Strategist", PerkinElmer
...#e23091 (pub.only): “Effect Of Bavituximab In Combo w/Nivolumab on Tumor Immune Response in a 3D ExVivo System of Lung Cancer Patients”, Senior Author: Soner Altiok, Moffitt CC

Jun18-20: ICDS’17, Annual ICDS Conf. on Cell Death in Development & Disease, Israel
...Jun20 11:30pm: Raymond Birge (Rutgers), “Regulation of Efforocytosis by Phosphatidyserine Receptor”
Jun19-22/Avid Booth #1411: BIO Intl. Convention, SanDiego

Jul7: PPS must be $1+ by July7, then 10 trading days at $1+ by July21 to avoid a R/S of up to 1:7.
~Jul13: FY'17Q4 (fye 4-30-17) Financials & Conf. Call -
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call -
Sep25-28/Avid Exhibiting: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston

~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: )

SCIENCE: "Evolution has favored pathogenesis that resembles apoptosis."
Dr. Judah Folkman: ”This [Thorpe’s VTA research] is very promising and very elegant work... The whole goal is really 2-part, reducing the harsh side effects of cancer treatment, and reducing the chance that some cancer cells will evade treatment. That would be a big step in the next decade, and anti-vascular therapy will play a major role." (’97 & ’02 &
Peregrine's Bavituximab Clinical Trials website:
Bavituximab MOA & Clinical Data:
...Bavi Publications:
...Bavi Posters & Presentations:
Bavi MOA: Video (3:34) added ~3-2014 "Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer"
Bavi MOA: Video (1:33) on Bavi’s Immunotherapeutic MOA added to Youtube on 3-27-14

BAVI MOA 4-3-17 AACR'17: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster: “PS Targeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma”
BAVI MOA 1-30-17 Mol.Cancer article: MDA/J.Fleming, UTSW/Brekken, “PreClin. Eval of DNAtrix's DNX2401+BAVI for Pancreatic Cancer”
...Combo DNAtrix's DNX-2401(Oncolytic Virus) + BAVI “significantly inhibited tumor growth; further enhanced its anticancer activity; warrants further clinical evaluation...”
BAVI MOA 11-14-16 SITC’16: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster on Triple Combo Rad+Bavi+aPD1 vs. Melanoma
...Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." => AACR'17 Update 4-2-17 (#574)

BAVI MOA 10-22-16: Duke’s Herbert K. Lyerly (w/PPHM) poster on AntiPS/TNBC data at AACR’s Tumor Immunotherapy Conf./Boston
...”Modulating The Tumor Microenvironment to Enhance Cancer Immunotherapy by Inducing Phosphatidylserine Expression on the Tumor Surface”
BAVI MOA 9-27-16 AACR-CRI/Dr. Michael Gray: Preclin. Triple-Combo Bavi+PD1+LAG3 TNBC data in TNBC (80% Compl. Regression, Stat-Sig. Incr. in Key Tumor Fighting Immune Cells)
BAVI MOA 7-27-16 Shaul/Brekken/Thorpe/etal PLOS ONE article: Fhu/Bavi vs. APS-related Pregnancy Complications & Thrombosis
...”The potential clinical impact of 1N11 (Fhu Bavi) in patients with APS is substantial. Spring-boarding from the present discovery of 1N11 as a highly-effective, mechanism-based treatment for APS in a comprehensive series of mouse models of APS-related disorders, clinical studies of 1N11 now warrant consideration.”
BAVI MOA 5-11-16 Breast Cancer Res. article, B.Freimark/M.Gray/CW.Hughes-et-al, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC”
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”
BAVI MOA 4-20-16/AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active”
BAVI MOA 1-18-16: CEO Steve King explains PPHM's direct PS-Targeting advantage vs. the “individual-receptors” PS-binding approach of others like: Axl Mer TIM-3 RAGE Tyro3 GAS6 CD300a BAI1 MFG-E8 etc.
2-2016: Rutgers' Dr. Raymond Birge's relationship with Peregrine & UTSW's Dr. Rolf Brekken and his 2-26-16 article, “Phosphatidylserine is a Global Immunosuppressive Signal in Efferocytosis, Infectious Disease, and Cancer” and 9-26-16 AACR/CRI, “Characterization of a PS, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer”

11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (DUKE's Herbert K. Lyerly + PPHM + UTSW)
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
BAVI MOA 8-26-15: Jeff Hutchins(VP/PreClin-Res) ImVacS’15 Talk – 29pg. Slideshow
…“Expansion & Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides):
BAVI MOA 2-9-15: PPHM's Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides:
BAVI MOA 12-12-14 San Antomio Breast Cancer Symposium, Dr. Bruce Freimark, Bavi+anti-PD-1 vs. Breast Cancer
BAVI MOA 11-2014 SITC’14: 3 posters on preclin. Bavi+aCTLA4/aPD1 combo data (Hutchins Freimark Brekken Huang etal)
BAVI MOA 8-28-14: Italy’s Dr. Federico Cappuzzo, Bavi/NSCLC profile article (DovePress OpenAccess, 7pgs) -
BAVI MOA 8-11-14: PPHM/VP Dr. Jeff Hutchins’ presentation at ImVacS "Immunotherapies & Vaccine Summit", Boston - PR: ; PDF(31 Slides):
...MLV’s Dr. George Zavoico’s 8-27-14 report on Dr. Jeff Hutchins’ 8-11-14 ImVacS/Boston Bavi MOA presentation:
BAVI MOA 5-28-14: Dr. Rolf Brekken’s 47min CRI “Cancer Immunotherapy” webinar about Bavituximab as an Upstream/Global Immune Checkpoint Inhibitor – REPLAY:
. . .CRI=Cancer Research Institute (NYC – Supported by BMS): - Facebook: ,
. . .CRI launches “Answer to Cancer” (cancer immunotherapy) website
. . .8-12-14: CRI adds Youtube links to the 5-28-14 CRI Immunotherapy webinar, incl. Dr. Brekken's talk "about Bavi and how it works against lung, liver, and other kinds of cancers"
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade”  (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt
......**A/o 9-2015, Dr. David Carbone (PPHM SAB/KOL) is President of IASLC
BAVI MOA: 12-2013 Bavi’s Immunotherapeutic MOA overviewed by UTSW’s Brekken/Huang in Pan European Networks Jrnl.
BAVI MOA 11-9-13: Annual SITC (WashDC) – 2 posters about Bavi’s Immunostimulatory MOA
...“We are actively working towards initiating a clinical trial in the coming months to further investigate the potential synergistic effects of bavituximab and an approved [anti-CTLA-4] immunotherapy in patients with Melanoma."
10-28-13 IASLC/Sydney: “Immune Checkpoints in the Tumor Environment: Novel Targets & the Clinical Promise of Combined Immunotherapies”   
…Symposium speakers: Scott J. Antonia/MD-PhD(H.Lee Moffitt CC), Dmitry I. Gabrilovich/MD-PhD(Wistar Inst), Rolf A. Brekken/PhD(UTSW), David E. Gerber/MD(UTSW)
BAVI MOA: 8-19-13 Data Supporting Bavituximab’s Immunotherapy MOA Published in “Cancer Immunology Research” (AACR) - (PDF)
…“PS-Targeting Antibody Induces M1 Macrophage Polarization & Promotes Myeloid-Derived Suppressor Cell Differentiation” (Thorpe etal)
BAVI MOA: 8-13-13 PPHM/VP Dr. Jeff Hutchins’ Presentation on the Downstream Immunostimulatory Effects/Moa of PS-targeting antibodies (like Bavi) at CHI’s “Immunotherapies Congress”/Boston
BAVI MOA: 10-12-12 NMB article on how Bavi "Induces Innate & Specific Anti-tumor Responses"
BAVI MOA: 5-1-12 Dr. Phil Thorpe's 46min talk at NYAS PS-Targeting Symposium
. . .Symposium title: "Phosphatidylserine (PS) Asymmetry - Therapeutic Apps. in Cancer & Infectious Disease Symposium"
. . .Replays of 5 speakers: Alan Schroit, Chris Reutlingsperger, David Ucker, Ari Helenius, Philip Thorpe
BAVI MOA: 5-26-11 Dr.Thorpe's keynoter at Recombinant-Mabs/Barcelona &
BAVI MOA: 4-2010 Thrombosis Research article (Dr.Thorpe) 
FTM's 12-2012 post giving links to 46 Cancer & Immunology journals & websites:
Peregrine's SRB - Links to Profiles & Pubmeds:
Expert Quotes/Commentary On Bavituximab's Moa/Potential:
Peregrine's Patent Estate - excl. licenses from UTSW MDA U-CALIF USC:
7-16-12 Form 10-K (fy/e 4-30-12): License Agreements between PPHM & UTSW/DNA/Avanir/Lonza (pg.10)
…Royalty %'s payable to UTSW/Dallas on sales of future-approved Anti-PS drugs will be in the "low single digits"
4-2006: Tarvacin (chimeric 3G4) will henceforth be referred to by its generic name, BAVITUXIMAB, to avoid confusion with OSI's anti-cancer drug Tarceva.
- - - -Peregrine's Anti-PS Mabs:
• PGN635 (B2GPI-dep.) is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type”
• PGN632 (B2GPI-indep.) is the Duke-PPHM-HIV candidate=11.31=AT005; also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see
• PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see . 124I-PGN650 is Peregrine’s PS-Imaging candidate (see )
BETABODIES (Clipped/Nicked B2GPI - ex: KL15, “2nd-gen. PS-Targeting”) - bind to PS directly, are smaller in size (100 vs. 250KDa) and have a longer serum half-life (~5days) than natural antibodies (Bavi=~1day) – see
…2/17/15: UTSW/PPHM’s BetaBodies patent#8,956,616 Awarded(Granted)

Examples of anti-PD-1 drugs in development: (PD1=”Programmed Cell Death Protein 1”)
1. Merck’s Keytruda(pembrolizumab=MK-3475, formerly=labrolizumab) <=’14/Melanoma, ‘15/NSCLC, ‘16/Head&Neck
2. BMS’s Opdivo(nivolumab) <=’14/Melanoma, ’15/NSCLC & RenalCell
3. AZN/MedImmune’s MEDI0680 (formerly=AMP514)
4. GSK’s AMP-224 (collab. with Amplimmune)
Examples of anti-PD-L1 drugs in development: (PD-L1=”PD1 ligand”)
1. BMS’s BMS-936559 (MDX-1105)
2.. Roche/DNA’s Tecentriq(atezolizumab, aka MPDL3280A) <=2016/Bladder & 2L/NSCLC
3. AZN/MedImmune’s Durvalumab (MEDI4736)<=2015 PPHM+AZN collab. & expansion to run trials in Lung & "mult. tumor types"
4. Pfizer/Merck-KgaA’s Avelumab (formerly MSB0010718C)
7-14-14/CC: Steve Worsley (VP/BusDev) said that Peregrine is “seeking collaborators that build on other checkpoints of pathways such as PD-1, IDO, immune-stimulatory drugs, and even vaccines…”
...Interesting: PPHM KOL/SRB’r Dr. Scott Antonia’s (Moffitt-CC/Tampa) role in IDO dev: <=“1st to report in 2002 that IDO inhibitors delay growth of human lung cancer cells”
Incyte’s immune checkpoint inhibitor INCB24360 is an oral inhibitor of IDO1 (indoleamine dioxygenase-1) –
NewLink Genetics’ immune checkpoint inhibitor indoximod is an oral inhibitor of IDO (indoleamine 2,3-dioxygenase) –
...“IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4 & PD-1 that represent potential breakthrough approaches to cancer therapy.”

.."As of 4-30-16, we employed 281 full-time emps & 3 part-time emps." ('11=154/2, '12=172/2 '13=182/4 '14=180/4 '15=211/4)
...On 3-18-09, CFO P.Lytle (Cowen/Boston) stated, "We have 135 emps, 85 under Avid Bioservices, and the remaining 50 emps reside at the Peregrine corp. level - 35 in R&D & 15 in G&A."
In 10-2009, Dr. Robert Garnick joined Peregrine as Head/Regulatory ( ).  In his 24 years at Genentech (1984-2008; from Feb'01-Oct'08 as Senior V.P. of Regulatory, Quality & Compliance), he was responsible for 17 new product approvals, including most of DNA's top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin, and Lucentis.  He was responsible for all the regulated aspects of Genentech's business, including drug development, commercial production, and promotional & labeling compliance.  As CEO Steve King said 6-29-11, "Rob is the ringmaster."
• See this 6-29-11 Minyanville article, "Peregrine Pharma's Secret Weapon"
• Examples of Dr. Garnick's work at Genentech on Avastin (bevacizumab) approvals:  
• All of Dr. Robert Garnick's public comments (thru 3-7-2014) while at Peregrine:

Latest 10K 4-30-16 iss. 7-14-16 PR: (Cash 4-30-16=$61.4mm)
Latest 10Q 1-31-17 iss. 3-13-17 PR: (Cash 1-31-17=$41.5mm)
ALL SEC filings for PPHM:
PPHM's Corp. Bylaws (a/o 11-14-14):
Poison Pill adopted 3-16-06: - 44-pg SEC filing: ...BUNGLER explains in plain language:
5-15-17: Parties Settle 2013 Shareholder Derivative CA Lawsuit vs. BOD(re: Fiduciary Duties)
Shares O/S as of 3-10-17=297,709,478 - history since 4-2006:
...A/O 1-31-17: 273,280 warrants o/s with wgt.avg. exercise price of $2.47 -- 29,467,870 stock options outstanding at a wgt.avg. exercise price of $1.26. (pg.14 10Q)
4-12-17/8K: Nasdaq Delisting Notice($1 min.), 4-10-17 deadline missed; Peregrine to Appeal for Extension
...6-7-17/8K: Hearing Panel Grants Extension until 7-21-17 (must be over $1 by 7-7-17)
4-13-14: PPHM Registers $30mm of 10.50% Series E Convertible Preferred Stock and $25mm ATM Common Stock in 2 424B5’s: &
12-27-13: S-3 Registration, “up to $100,000,000”, Common & Preferred
…Of note, this name on the S-3 cover: Michael A. Hedge (Leader, Life Sciences M&A team), K&L Gates LLP, Irvine, CA
...2-5-14: PPHM Announces Public Offering of 10.5% Series E Convertible Preferred Stock
...2-11-14: PPHM Raises net $16.2mm selling 700k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh (8-K)
...6/14/14-7/14/13: PPHM Raises net $9.5mm selling 400k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh (4-30-14 10-K pg. F-34; $20mm gross remaining)
12-23-14: S-3 Registration, “up to $150,000,000”, Common & Preferred
A-T-M (At-The-Market) Sales 3/2009 - 3/13/17 ($262,201,000gr./227,346,867sh=$1.15/sh):

...12-29-10: ATM Agreement (up to $75mm) with MLV filed - 8K:
...3-9-12: PPHM files shelf to sell up to $150mm common stock, warrants, S3:
...12-28-12: New ATM Agreement (up to $75mm) with MLV filed - 424B5:
…8-7-15: New ATM Agreement (up to $20mm) with NOBLE filed - 424B5:
…8-7-15: New ATM Agreement (up to $30mm) with MLV filed - 424B5:
INSIDER-Trans: &
Inst. Holdings ( - updated qtly, 45-days after each q/e cutoff:
Short Interest, upd. twice a month: ...Updates 1 day earlier:
Nasdaq Last Sale (NLS) & Official Close for TODAY: DETAIL:
Currenty Halted Stocks: 
Director Eric Swartz's Jan-Feb'10 Buying Streak (100k @ 3.12/sh.):
6-30-14: SABBY MGT. (led by Hal Mintz) holds 291600/PPHMP a/o 6-30-14 ($7.0mm@1.66/sh. common):
6-20-17/13D: Ronin Capital+SWInvest (John Stafford III+Stephen White) add 2,647,193 shs. COMMON during Mar10-June16.
...Their 13D 'Group' stake now 8.8% of COMMON (26,313,734sh.) & 7.5% of PREFERRED (123,499sh.) - see:

...NOTES: As a Group, ie, “people that share the furtherance of a common objective/concerted action”; 13D’s are reserved for ACTIVE INVESTORS who may be “interested in agitating for some kind of a change at the company”.
3-31-17: Tappan Street Partners ( opens 6,400,000sh. position - see Nasdaq/Tappan
10-30-15: Kenneth Dart (Eastern Capital) acquires 13.1% stake (30,106,945sh.) in PPHM
...2-14-12: Kenneth Dart adds 3,460,192, now 7,421,760 (8.55% a/o 12-9-11) (13G)
...2-13-13: Kenneth Dart adds 500,000, now 7,921,760 (5.9% a/o 12-31-12) (13G)
...2-13-15: Kenneth Dart PPHM stake now 9,921,760 (5.4% a/o 12-31-14) (13G)
...10-30-15: Kenneth Dart adds 18,518,518@$1.08, now 30,106,945 (13.1% a/o 10-30-15) & (13G & Form3)
12-31-14: BlackRock Inc. (Larry Fink, CEO) accums 2.0% stake (4.6mm sh.) in Peregrine.
...12-31-13: BlackRock increases PPHM stake to 10,279,810
...12-31-14: BlackRock increases PPHM stake to 12,130,885
...12-31-15: BlackRock increases PPHM stake to 12,353,101
...6-30-16: BlackRock decreases PPHM stake to 4,633,699

9-8-11: Roth arranges direct sale of 6,252,252sh.@$1.11 to 3 inst's, net=$6.5mm
10-19-09 PPHM executes 1:5 R/S to regain Nasdaq $1 min-bid compliance:
Current PPHM Stock Chart:

8-6-10: Bavituximab listed #8 in EP-Vantage's 'Biggest Unpartnered Pipeline Assets' chart, with NPV=$1.022b:
5-22-13: Citigroup analyst Andrew S. Baum’s report, "Immunotherapy - The Beginning of the End for Cancer"
…”A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history… We believe this market will generate sales of up to $35B/yr. over the next 10 years and be used in some way in the mgt. of up to 60% of all cancers…”
Noble Financial/Kumaraguru Raja (init. 7-16-15), 7-15-16: Buy/PT=$1.50
Roth Capital /Joe Pantginis (init. 7-15-10), 7-15-16: Neutral/$.50 <="In Transition" a/o 12-2016
FBR & Co./ThomasYip 9-9-16: Outperform/PT=$1.00
MLV/George B. Zavoico(Jones Trading?) - init. 2-8-10 Buy/PT=$10, CURR: Buy/$3.50 <=dropped 2015
Piper Jaffray/Charles Duncan - init. 3-5-13 <=Coverage dropped 12-2015
JMP Securities/Jason Butler - init. 8-30-2011 OutPerf/PT=$5, CURR: OutPerf/$6.50 <=7-2014: dropped from
LifeTech-Cap/Steve Dunn - init. 4-14-10 Spec-Buy/PT=$8, CURR: Spec-Buy/$5 <=Dropped 4-2012
1-2011: PPHM has Exec. Info. Report (EIO) prepared by Crystal Research (Jeffery Kraws):
12-21-07/Terminated: Rodman&Ren. (Jaikaria/Benjamin) initiate: Mkt-Perform:

AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary):
3-13-17: PPHM's Revs & Burns By Qtr Table, FY'07/Q1 thru FY'17/Q3 (q/e 1-31-17): (since 5-2006: Avid=$213.3mm, Total=$239.9mm, incl.Govt)
......Avid FY17 (fye 4-30-17) revs guidance upped: $60-65mm; committed backlog=$70mm. Recently Leased +42,000sf in same bldg. as MYFORD for future expansion. Expect future sustainable profitability for the co. in 15mos.”
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L".
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17:
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
2-28-17: Avid & Cook remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”):
6-2-16: Corp.Update – Avid Expansion & Drug Development -
5-23-16: Pete Gagnon (100pubs/presentations, 12+patents, 30 pending patents) Appointed VP/Process-Services of Avid – See Oct'15:
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs)
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion
6-17-15: Avid’s John Haney (ex-Genentech/Pfizer) speaking at BIO-INTL’5/Philly &
...”Designing & Implementing Avid’s New State-of-the-Art Single-Use Facility for Late Ph.3 & Commercial Prod.” - SK: "We've seen tremendous interest for production in the new facility, both from new & existing clients"
12-10-14: Avid to Double Mfg. Capacity (“expanding client roster; potential commercial launch of bavituximab”) &

3-24-15: Avid Receives CMO Leadership Awards for Its Commitment to Innovation & Reliability
3-12-13: Avid Q3'FY13 GP=$3.3mm; S.King 3-2012, "We have a profitable CMO, Avid Bioservices"
2-26-13: Avid Presents QbD/CPPs/CQAs at "BiopharmDev/Prod-Week"
4-2-12 AACR'12: Avid presents New Mab-Eng. Process (Fc/ADCC), Client Proj. (see #2510)
6-14-10: Avid adds 'Line #4 FILL-FINISH' capability,
5-3-10: PPHM leases addl. 11,000sq adjacent space (Avid exp?):
9-21-09: Avid becomes sole U.S. W.Coast CMO in Boehringer Ingelheim's Global Prod. Alliance Network
11-10-08: Avid expands capacity by adding 100L & 1000L Hyclone bioreactors:
6-25-08: Avid Selected as 1st U.S. CMO for DSM/Crucell's PER.C6 Cell Line:
7-14-08: Avid is CMO for Arius Research's lead drug, "AR001 Targeting CD44":
...7-23-08 Roche buys Arius for $190mm:

...Excellent Exosome (aka microparticles, microvesicles) info:
6-22-17: Nature/BJC article, Dr. Alan Schroit/UTSW etal: "Detection of PS+ Exosomes for the Diagnosis of Early-Stage Breast & Pancreatic"
2-9-17/PR: PS+ Exosomes Proof-of-Concept Data (N=44, Ovarian, Dr. Alan Schroit/UTSW etal) pub. 1-22-17 in OncoTarget
...Data (blinded plasma from 34 O.C. pts & 10 healthy subjects) supports the “high diagnostic power” of PS+ Exosomes in Ovarian Malignancies.
...Dr. Stephen Worsley (VP/BusDev): “...we believe this has potential app's in several solid tumors beyond ovarian cancer. With that in mind, we look forward to aligning with a partner to help explore the potential of this promising technology."
...PPHM’s PS Exosomes platform advantages outlined: UTSW/website and World Patent #WO/2016/201064:
......U.S. Patent app. #20170146542 “DIAGNOSTIC TEST FOR EARLY STAGE CANCER” pub. 5-25-17 (A.Schroit, S.Ward, A.Gazdar)
7-14-16: Peregrine Licenses Exosome-based technology from UTSW (Inventors: Alan Schroit/Philip Thorpe)
...“relates to assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample as a way to detect cancer at a very early stage of development.”
...Dr. Jeff Hutchins (VP/PreclinRES): "Once we have successfully validated this assay, we plan to establish proof-of-concept through an efficient preclinical & clinical testing pgm. We have no intention of conducting further development work beyond the proof-of-concept stage. Rather, we expect to initiate partnering discussions for commercialization of this pgm in 2017.

NCCN Bavituximab Trials Announced 9-6-16 - To Begin "Early 2017"
#1: Ph1/HepC-Related Hepatocellular(Liver) (Bavi+RAD+Bayer’s Nexavar=Sorafenib), MOFFITT CC (N=18)
. . . . . . .PI: Jessica Frakes, MD <=Recruiting a/o 3-27-17
#2: Ph2/Newly Diag. Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. & DANA FARBER (N=36)
. . . . . . .PI: Elizabeth Gerstner, MD <=Recruiting a/o 6-16-17
#2: Ph2/Newly Diag. Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. & DANA FARBER (N=36)
#3: Ph2/Progressive Squamous Head+Neck (Bavi+Merck’s Keytruda), JOHNS-HOPKINS(Sidney Kimmel CC)
. . . . . . .PI: Ranee Mehra, MD - See Dr. R.Mehra Jan'17/IFN-y Biomarker:

A. Phase III Bavi+Doce vs. 2nd-Line NSCLC "SUNRISE" (randomized, double-blind, placebo-ctl'd, n=582)
USA Protocol: <=chgd. to "Active, Not Recruiting." 2-1-16
...2 ARMS: A=BAVI/3mg+DOCE(Weekly), B=Doce+Placebo(Weekly)
...ECOG's: Ph3SUNRISE/0-1, Ph2Bavi+Doce(n=120)/0-1-2, Ph2Bavi+Durva(AZN)/0-1, Ph3Herbst2010/0-1 (2L/NSCLC)
...161 sites a/o 7-9-15 (USA/39 Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) - Growth:
...Sunrise Biomarker studies - 4 announced thru ASCO'17, see
......#1 10-10-16/ESMO’16: B2GPI/200-240(30%pts) StatSig MOS 7.7=>13.2mos.
......#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways: Pts Benefiting from Bavi+Doce” <=Presentation CANCELLED/”Anal.Not.Finished(IR)”
......#3 4-3-17/AACR'17: "IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” See:
......#4 6-3-17/ASCO'17: "Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” See ASCO'17:
2-25-16: IDMC Halts SUNRISE at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations”
...CC Replay: 12:22/Q&A: RahulJasuja/Noble, “You said that the performance of the Doce/Ctl arm was higher than ever seen in such a trial?” - SK “Yes, we've never seen these #'s reported. It's quite perplexing… at this point, the performance of the Doce arm was just completely out in left field.”
2-1-16: SUNRISE Trial status updated: “Study ongoing, but not recruiting.”
12-10-15: “Sunrise >90% enrolled; sufficient to allow the 2 planned interim looks (33%/50%) & final readout based on PrimEndPt=OS”
5-31-14 ASCO’14: David Gerber/Joe Shan Poster on Ph3/SUNRISE Trial (#TPS8129)
3-7-14: PR & Conf-Call: "first patients enrolled and dosed."
1-6-14: FDA grants FAST TRACK status to Bavi in 2ndLine NSCLC
12-30-13: Pivotal Ph.3 ‘SUNRISE’ NSCLC Trial Initiated (n=~600, sites=100+)
5-20-13: FDA Approves Bavituximab Ph.III Design for 2L/NSCLC; 600-pt trial to begin by y/e’13
...S.King: “We will now focus on starting the Ph.III trial while continuing ongoing partnering discussions.”
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."

==> PR=Partial-Resp(30-99% Red.), SD=Stable-Disease(29% Red.-19% Incr.), OR=Obj-Resp(PR+CR)
6-2012: FTM's charts of MOS Data from CtlArms(chemo) of Comp.Trials for 1NSCLC 2NSCLC PANCRE trials
11-25-11: Comp. of Bavi+Chemo vs. Avastin & Chemo-Only in 3 completed Ph.2 single-arm trials (ABC/2 & NSCLC):
O. 6th IST Trial: Bavi+Ipilimumab(Yervoy) vs. Adv.Melanoma (Ph1b, random, open-label, 2arms, n=24)
Protocol (UTSW): (PI: Dr. Arthur Frankel - see "Researching for Cures" )
UTSW's listing:
…Note: Ipilimumab = BMS’s “Yervoy” (anti-CTLA-4)
...12-10-15: “Due to newly-appr. therapies & chgs in SOC [ex: Keytruda/Opdivo: less-side-effects], enrollment recently stopped by UTSW.”
...4-23-14: Bavi+Yervoy IST trial initiated: 

N. 5th IST Trial (Bavi+Capecitabine+RAD) vs. Rectal Cancer (Ph1, open-label, 1arm, n=18)
...Note: Capecitabine (prodrug of 5-FU) = Roche/Genentech's Xeloda - see
...11-1-15/RadiationOncology – prelim. results/8 evaluables
…...”Of the 7 pts that proceeded to surgery, 1 demonstrated a pathologic complete response.”
...7-16-12: IST (Rectal) initiated at UTSW (PI=Jeffrey Meyer), ~18 patients -

M. Tumor Imaging & Dosimetry trial of I124-PGN650 (FH-Bavi) in Adv. Solid Tumors (Ph0, open-label, 1arm, n=12)
..."I124-PGN650 is the Fab end of PS-targeting mab PGN635 (FH-Bavi) joined to the PET imaging radioisotope iodine-124, a new approach to imaging cancer."
5-1-15: Interim Results/8pts (Jrnl Nuclear Med, vol56 suppl#3)
…”124I-PGN650 is safe and results in acceptable dosimetry and needs further optimization as an imaging agent based on the level of increased tumor uptake on PET/CT”
...6-28-12: Trial added to, 1st site "recruiting" (Wash.UnivSM/St.Louis)
…4-3-12: Peregrine Launches PS-Targeting Clinical Imaging Pgm (AACR'12 #2452) &
L. 4th IST Trial (Bavi+Cabazitaxel vs. 2nd-Line PROSTATE(CRPC) Cancer, open-label Ph.1B/IIA) *CANCELLED due to chg. in SOC Drugs*
Protocol: (CRPC=Castration-Resistant Prostate Cancer)
...Note: Cabazitaxel = Sanofi-Aventis' Jevtana - see
...3-12-13: CRPC IST cancelled (Slow-Enroll/2 New SOC Drugs): 
...5-25-11: IST (Prostate) initiated at UCI -> moved ot Med.Univ.SCar (PI: Michael Lilly), ~31 patients -
K. 3rd IST Trial (Bavi+PemCarbo vs. Frontline NSCLC, open-label Ph.1B, n=25)
…10-30-14: Interim data n=23, MSTO’14: MOS=12.2mos (hist-ctl ~10mos), PFS=4.8mos, ORR=35%
...9-9-14: Stage IV NSCLC IST Enrollment complete.
...4-2012: shows 2nd site added: Univ. of Pittsburg (PI=Liza Villaruz, MD)
...4-2-12 AACR'12: "5pts. to-date, 3 have PR's" (see #1744)
...3-8-11: IST (NSCLC) initiated at UNC (PI= J.Grilley-Olson), ~25 patients -
J. 2nd IST Trial (Bavi+Paclitaxel(Taxol) vs. Her2- Met. Breast Cancer, open-label Ph.1, n=14)
...3-31-15/A.Stopeck article(Ph1 data) “Cancer-Medicine” N=13: PFS=7.3mos, ORR=85%, 2 CR's
…6-3-13: ASCO’13/interim data, n=14: ORR=85%, 2 CR’s (15%)
...4-29-13: Enrollment complete.
...4-3-12 AACR'12: "5pts. to-date, 2 CR's, 1 PR" (see #4404)
...1-19-11: IST (Her2- MBC) initiated at Arizona CC (PI=A.Stopeck), ~14 patients -
I. Phase II Bavi+GEM vs. Front-Line Adv. PANCREATIC (randomized, unblinded, n=70)
Protocol: (15 U.S. + 4 Ukraine = 19 as of 6-7-2012)
…1-22-13: FTM's post of 13 Ph3 Gem+Treatment Pancreatic Trials ('02-'13) - Mean MOS: GEM=6.4mos., GEM+TR=7.3mos.
......Another FTM Pancreatic Phase3 trials table showing HR's, P-Values, and ORR% stats:
…6-3-13 ASCO’13/final data: n=70, Ctl=>Bavi MOS 5.2=>5.6mos, ORR 13%=>28% HR=.75
......Promising ‘immuno-indicative’ 1yr SURVIVAL results: GEM-Only(n=31): 0%,  Bavi+GEM(n=32): 24.5% - see:    
...2-13-13 Topline Data: “Bavi+Gem resulted in more than a doubling of ORR”
...6-25-12: Enrollment complete.
...6-20-12: Early data (cutoff=6/6/12 bavi=15 ctl=17) presented at AACR Pancreatic Conf.
...1-5-11: U.S. Ph.2 randomized trial initiated "up to 70 front-line patients at ~10 clinical sites."
H. 1st Investigator-Sponsored (IST) Ph.I/II Trial (Bavi+Sorafenib vs. Liver Cancer/HCC, open-label, n=9+38=47)
...Note: Sorafenib = Onyx/Bayer's Nexavar - see
Protocol: UTSW:  (5 sites: 3/UTSW, Parkland-Hosp, Dallas/VA, PI=Dr. Adam Yopp)
...3-25-15: Dr.Adam.Yopp(UTSW) Oral-pres./SSO (Liver-IST/Ph2-data) N=38(79%HepC, ECOG/0=34%): MTTP=6.7mos, MOS=6.1, MDSS=8.7, DCR=58%
...1-16-15 ASCO Gastro-Symposium: Ph.2 data/n=38 (Adam Yopp), “These clinical outcomes of TTP=6.7/DCR=58%/PFS=4mo are quite encouraging…”
...11-8-14 SITC'14: Ph.2 Correlative Studies data (biopsies B4/After) on 6pts, incl. KOL Dimitry Gabrilovich’s comments:
...9-9-14 Enrollment complete.  (ph2=38  Ph1=9)
...4-4-12 AACR'12: Dr. Adam Yopp, "promising safety profile to-date" (see #5591)
...Feb'12-Sep'14 10+ times: CEO Steve King hints of future ex-US partner-driven Bavi+Sorafenib/LIVER trial in Asia-Pacific:
......Articles & Data describe Liver Cancer challenges in Asian populations: &
...12-1-10: PPHM's 1st IST (Liver Cancer) initiated at UTSW, ~56 patients -
…Per S.King, 5-18-10/R&R, "We've had a lot of interest in running clinical trials with the compound from investigators who have either had prior experience with the drug or would like to study the drug in various settings. Potential IST indications include all the major solid tumor types. Of particular interest is Liver Cancer, in which we have a natural tie-in with our HCV program, Ovarian Cancer and Pancreatic Cancer, also very nicely supported by the prior data."
G. Phase IIb Bavi+PC vs. Front-Line NSCLC (randomized, unblinded, 'confirmatory', n=86)
Protocol: (17 U.S. + 9 India + 2 RepGA + 7 RussianFED + 5 Ukraine = 40 as of 8-12-11)
...Also listed in: India's CTRI registry and WHO's registry
...6-27-13: Bavi+CP MOS>14mos (“with < 60% of survival events”)
…”with less than 60% of survival events, while the Bavi+CP arm currently demonstrates a MOS > 14mos, there was not a meaningful enough diff. in survival between the 2 arms that would support the advancement of this combination. Full results will be presented at a future sci. meeting or thru pub.”
...5-7-13: FTM's Table of 20 prev. Ph.3 Trials in 1st-Line NSCLC (ctl=CP), MOS & HR results (Note Avastin improved CP-Only by 19%):  
...3-9-12: Topline ORR & PFS Data (Bavi+PC vs.PC-only)
…...LOCAL reads: ORR/32%-31% PFS/5.8-4.6mos , CENTRAL reads: ORR/25%-23% PFS/6.7-6.4mos
...12-6-11 Prelim. Data (n=86, 100% Stage IV's) => ORR=39%, PC/alone=25%:
......Comp. vs. Avastin+PC/Ph3/n=417(74% Stage IV's): ORR=35% (Sandler/E4599/2006 )
...9-8-11: Enrollment complete.
...7-14-11/CC: Enrollment was taking longer than expected; have amended protocol; expanding to 30+ sites, expect enroll. comp. "in coming weeks", interim data by Yr-end'11.
…7-14-10/CC, J.Shan (VP/Clin+RegAffairs): "This trial is intended to confirm in a randomized setting the results from our Ph.2 signal-seeking NSCLC trial which showed 43% ORR, more than double the generally accepted chemo ORR of under 20% in numerous publications. Favorable results could then lead to an end of Ph.2 meeting with the FDA, with possibly a pivotal Ph/3 trial for front-line lung cancer, our 2nd potential regulatory pathway for bavituximab."
...7-14-10: U.S. Ph.2b randomized trial initiated
……up to 86 front-line patients at ~20 clinical sites; goal: enrollment comp. by mid'11.
F. LEAD IND: Phase IIb Bavi+Doce vs. 2nd-Line NSCLC (randomized, double-blinded, placebo-ctl'd, n=120, 'registrational')
Protocol: (24 U.S. + 15 India + 2 RepGA + 7 RussianFED + 5 Ukraine = 53 as of 8-12-11)
Enrolled Oct2010 - Oct2011 at 40 global sites (per J.Shan 9-7-12 webcast ( ) 
8-2012: Compare Bavi+Doce's MOS=11.7mos (Bavi/3mg) to the 4 Curr-Approved 2Line/NSCLC Drugs
• Taxotere/docetaxel => MOS=6.3mos (meta-analysis of 5 trials, 865 pts)
• Altima/pemetrexed => No diff. vs. Docetaxel (Ph.3 non-inferiority vs. Doce, 571 pts)
• Tarceva/erlotinib => MOS=5.3mos (TITAN Ph.III n=424 trial - see )
• Iressa/gefitinib => "Iressa does not improve OS"
2-19-16/Clin-Lung-Cancer-Jrnl: Ph2 Final Data, Dr. David Gerber et al
9-8-15: CMS SETTLEMENT EXECUTED (CSM pays PPHM only $600k for their “breach of contract, negligence & constructive fraud”, due to “limitation of liability contract clauses”) (10Q/pg.17)
6-23-14: PPHM files Opposition to CSM’s Motion For Partial Summary Judgment - excerpts: 
. . .Declaration of Joseph Shan (VP/Clin+RegAffairs): 
. . .Declaration of Jeffery Masten (VP/Quality):  #6: “up to 25%" of CTL had 1mg, and “up to 25%" of 1mg had CTL(DoceOnly).
3-28-14: Peregrine files 1st Amended Complaint vs. CSM (13pgs)
...Pg6: ”[as of 4-15-10], CSM had already secretly & unilaterally swapped the A & B arms so that those patients that were randomized in the A arm (CTL) and supposed to receive placebo treatments, were actually receiving 1MG Bavi treatments, and vice-versa.  Peregrine’s Fall’12 investigation revealed that CSM committed other labeling & distribution errors affecting the A & B arms above & beyond the swap of the A& B arms noted above.”
6-3-13/ASCO’13: Final Data Ph.II 2L/NSCLC
…60% improvement in MOS: Bavi/3mg=11.7mos. vs. 7.3mos. for CTL-arm(combined Bavi/1mg + DoxyOnly arms), HR=.662, P=.113
5-20-13: FDA Approves Bavituximab Ph.III Design for 2L/NSCLC; 600-pt trial to begin by y/e’13
...S.King: “We will now focus on starting the Ph.III trial while continuing ongoing partnering discussions.”
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."

2-19-13: Topline Data Update from 2nd-Line NSCLC Trial after data discrepancies review
60% improvement in MOS: 3mg=11.7mos. vs. 7.3mos. for CTL-arm(combined 1mg & Doxy+placebo arms), HR=.73, p=.217
6-5-13: FTM's table of MOS data in 15 prior Doxy 2nd-Line NSCLC trials (Bavi's 60% MOS Improvement is Tops)

1-25-13: MLV's George Zavoico recaps 2ndLine/NSCLC data errors & current status of PPHM's review
...GZ: "This means that patients randomized into the high dose arm were administered Bavi correctly, whereas some of the patients in the placebo arm were administered low dose Bavi and some in the low dose Bavi arm were administered placebo. More importantly, the findings suggested that the MOS of 13.1 mos. in the high dose arm was likely to be valid.  Even by historical measures, this is a remarkable result, since docetaxel's product insert lists the MOS of NSCLC patients receiving this widely used drug as 2nd-Line therapy in 2 trials as 5.7 & 7.5 mos. In effect, adding Bavi doubled the MOS. In our view, this was an extraordinary stroke of luck. If the high dose arm had been affected by the coding discrepancy, Peregrine would have been in a completely different & unfortunate position… Moreover, Peregrine must determine how best to present its case to the FDA. Will the historical controls be sufficient to justify moving Bavi into a Phase III pivotal trial, or will Peregrine have to pool the results of the placebo & low-dose arms and use that as a comparator to argue for moving ahead?  A simple average of the placebo & low-dose arms results in a new control MOS of about 8.4 mos., still several months less than that of the high dose arm. This quick analysis results in about a 5-mo. survival advantage, a substantial prolongation for patients with second-line NSCLC and likely to justify moving Bavi into a pivotal Phase III trial in 2013, in our view."

1-7-13 PPHM PR - Review Update: "discrepancies are isolated to the placebo and 1 mg/kg arms; no evidence of discrepancies in the 3 mg/kg arm… Peregrine is taking a very conservative approach toward analyzing the results by combining the placebo & 1mg/kg arms into one treatment arm (control arm), and comparing to the 3mg/kg arm. This analysis indicates that the 3 mg/kg arm continues to show favorable TRR's, PFS, and OS over the new combined control arm. Peregrine expects to announce more detailed results from the analysis in the near term when it is completed."
9-24-12: Major Discrepancies found in 2nd-Line NSCLC Ph.2B Treatment Group Coding by Indep. 3rd-Party Vendor CMS/FargoND
…"Investors should not rely on clinical data that the company disclosed on or before Sept. 7, 2012 from its Ph.2 Bavi trial in patients with 2nd-Line NSCLC or any presentations or other documents related to this Ph.2 trial."
9-24-12: Peregrine sues CSM Over Bavi Ph.2B 2nd-Line NSCLC Clinical Trial Mix-Up
…CSM = Clinical Supplies Management Inc., Fargo ND
...1-17-13: Peregrine's lawsuit against CSM for "breach of contract & negligence" SERVED
…9-10-12 CEO Steve King, QtlyCC ( )
……"These are truly remarkable results (statistically doubling MOS) that are not only great for the pgm… but also great news for the NSCLC patients in the trial…"
…9-10-12 Robert Garnick (Head/Reg), QtlyCC ( )
……"The NSCLC data we announced 9-7-12 has far exceeded our expectations, and I hope that you're as excited as I am with bavituximab's potential. I feel strongly that Peregrine should be recognized for having the corporate courage to conduct the rigorous, randomized placebo-controlled Phase II trial that provided these robust data and that provide the basis for us to plan for a pivotal Phase III program."
...9-7-12: PPHM Press Release about Dr. Gerber's plenary at ASTRO/Thoracic/Chicago:
…"The interim data showed a statistically significant improvement in OS (Hazard Ratio 0.524, p-value .0154) and a doubling of MOS (11.1/13.1mos. vs. 5.6mos.) in the Bavituximab-containing arms compared to the [Docetaxel] ctl-arm."
......VP Joe Shan's 15min. Webcast & Slideshow recapping Dr. David Gerber's 9-7-12 ASTRO/Chicago Plenary:
…8-15-12 CEO Steve King, Wedbush/NYC ( )
......"As we're sitting here today, we have still not reached the # of events for MOS in either of the Bavituximab arms - and, in fact, we still have patients that are on treatments."  Q&A: "it's going to be a very positive MOS result, it's just a matter now of magnitude."
…7-16-12 CEO Steve King, QtlyCC ( )
......"The strength of this 2nd-Line NSCLC data (esp. MOS trends) in this large area of high unmet medical need has also sparked a surge in partnering discussions that has included over 15 in-person partnering meetings since that time with major players in oncology, with all discussions ongoing and addl. parties showing interest. Our goal for the program is to position ourselves, along with a potential partner, to initiate Ph3 by mid-2013, which means an EOP2 meeting by yr-end'12. It would be ideal to have a partner on board to participate in the EOP2 meeting, and we have communicated this to interested parties and they agree."
…7-16-12 Robert Garnick (Head/Reg), QtlyCC ( )
……"We've been working very hard and very actively on the next steps in our Bavi 2nd-Line NSCLC pgm, given the favorable data that we've seen. As you can imagine, with data like this, there are many things that we need to consider. One consideration is that, should the data continue to trend the way it is, particularly in survival, this opens a door for potential discussions around a pathway for Accelerated Approval. At this point, all options are being considered, with Peregrine working towards the most efficient path forward from a regulatory standpoint." Q&A: "…all in all, I think the data is extremely compelling and I think it makes a really good case. Certainly, I think, I've seen a lot of Ph2 & Ph3 data, and this is as compelling Ph2 data as I've ever seen. So, I'm very comfortable proposing a meeting with the FDA for Q4'12."
…7-12-12 CEO Steve King, JMP-Conf/NYC ( )
……"Re: 2nd-Line/NSCLC trial, the most thrilling thing is the fact that, even though we'd reached MOS for the ctl-arm(Doce) at end of Apr'12 of LESS THAN 6MOS, the majority of patients are still alive (today) in both Bavi arms, and we expect that to continue for some period of time still. Ph3 planning is underway already; our goal is to start this Ph3 by mid'13, meaning an EOP2 meeting with the FDA in Q4'12; our goal is to bring a partner on board, ideally in time for that EOP2 meeting, certainly before the beg. of the Ph3 trial."
…5-21-12: TopLine data n=117 for Bavi/3mg+Doce arm: ORR=17.9%/PFS=4.5mos (vs. CTL 7.9%/3mos)
......Importantly, MOS for CTL-arm "< 6 mos", but not yet reached in both Bavi arms.
...10-6-11: Enrollment complete.
...7-14-11/CC: Enrollment was taking longer than expected; have amended protocol; expanding to ~45 sites, expect enroll. comp. "early in Q4/2011", data unblinding 1H'12.
…3-17-10/Roth, CEO S.King: "We refer to this trial as a Registrational Phase II Study, because we believe that if we have results anywhere near approaching what we saw in the earlier [India] study, it could be a conduit for Accelerated Approval."
...6-4-10: Ph.2b randomized reg. trial Open for enrollment:
……"up to 120 refractory patients at ~30 clinical sites; goal: fully-enroll by mid'11, topline data by y/e'11."

These 5 completed Ph.1 & Ph.2 Bavituximab Cancer Trials archived to:
1. Ph.1A Bavi/Mono vs. Solid Cancers (USA n=26, 6/2005-6/2009)
2. Ph.1B Bavi+Chemo vs. Solid Cancers (India n=12, 11/2006-5/2007)
3. Ph.2 Bavi+Doce/BREAST/Refractory (RepGA n=46, 1/2008-5/2009): ORR=61%(Her2+=86%), PFS=7.4mos, MOS=20.7mos *
4. Ph.2 Bavi+PC/BREAST/Frontline (India n=46, 8/2008-9/2009): ORR=74%(Her2+=100%), PFS=6.9mos, MOS=23.2mos %
5. Ph.2 Bavi+PC/NSCLC/Frontline (India n=49, 6/2008-10/2009): ORR=43%, PFS=6.1mos, MOS=12.4mos #
......* BAVI+DOCE/Refract-MBC N=46: Compare *MOS=20.7mos to 11.4mos for Doce/alone (Nabholtz/JCO1999 Ph3/n=203 )
......% BAVI+PC/FrontLine-MBC N=46: Compare %MOS=23.2mos to 16.0mos for P+C/alone (Loesch/JCO2002 Ph2/n=95 )
......# BAVI+PC/Frontline-NSCLC N=49: Compare #MOS=12.4mos to P+C/alone=10.3, Avastin+PC=12.3 (E4599/n=434), achieved using less Chemo (175-v-200 & AUC5-v-AUC6), treating 16% (8/49) more-difficult Squamous in Bavi trial (excluded totally from E4599), and treating higher % of sicker ECOG1 pts than in E4599 (96%-v-60%). See 6-15-11/PR , ASCO'10 , and a discussion of differentiating factors between patient demographics & baselines treated in the 2 trials: .

9-9-11: PPHM is positioning Bavi as potential Interferon replacement in HCV cocktails:
12-2011: Nature Medicine article lists Peregrine among 11 co's dev. interferon-free treatments for HCV:
7-2011: Nature Biotechnology article quotes Dr. Thorpe on Bavi's goal to elim. IFN-A:
6-2011: Flying Publisher 'Guide to HepC Treatment' highlights Bavituximab:
D. Phase II Bavi+Riba vs. Frontline-HEPC (randomized, open-label):
Protocol (init=1-2011):
12-29-11: HCV Ph.2 Trial Update
……SK: " this is a good time to seek partners for the antiviral pgm. which has shown promise in this study."
9-26-11: Enrollment Complete in Bavi+Riba/HCV trial
1-10-11: Bavi+Ribavirin/HepC Ph.2 trial initiated
......"~66 patients with previously untreated genotype-1 chronic HCV, 1 of 3 arms (.3Bavi+R / 3.0Bavi+R / PEGIFN+R) for 12 wks, testing for safety & antiviral activity."
C. Phase 1B HCV-HIV Co-Infected's Mono Repeat-Dose Trial:
Protocol (init=7-2007):
…4-2-11: Ph.1B trial data presented at EASL-2011/Berlin on 4-2-11
…1-31-11: Enrollment Complete in HCV-HIV trial
...7-10-07: Enrollment begins at St.Michaels (Peter Ho Mem. Clinic, NJ)
......Ascending dose levels of Bavi weekly for 8 wks; ~24 pts; designed to assess Safety & PK, but "HCV & HIV viral titers & other biomarkers will be evaluated".
...5-17-07: New Clinical Protocol filed with FDA:
These 2 completed Ph.1 Bavituximab Hep-C Trials archived to:
1. Phase 1A Bavi/Mono Single-Dose HCV Trial: (init=8-2005 comp=2-2006 n=30)
2. Phase 1B Bavi/Mono Repeat-Dose HCV Trial: (init=6-2006 comp=1-2007 n=24)

3-13-17 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO SK: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO SK: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 Peregrine's ASM: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast:
9-8-16 Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Lytle) Transcript
...CEO SK: “Our ultimate goal remains to reach overall profitability within the next 21mos, and Avid will be an important driver for achieving that goal, in combination with making strategic investments in our R&D while pursuing partnerships to help advance our programs.”
7-14-16 Qtly. Conf. Call (King/Garnick/Hutchins/Shan/Lytle) Transcript (Avid revs guidance for FY17=$50-55mm, curr. committed B/L=$68mm)
...CEO SK: “The recent licensing of Novel PS Exosome Tech. for detection/monitoring of cancer from UTSW will allow the co. to continue its R&D activities with significant upside coming from partnering as we move towards profitability.”
6-2-16: Corp.Update – Avid Expansion & Drug Development -
...Avid Revs for FY16(fye 4-30-16) will be $44mm; B/L=$56M; FY17/guidance=$50-55mm(3 curr. clients). Avid III being designed/already secured 25,000sf loc/expect complete=1H/2017. “Expect future sustainable profitability for the company in 24mos.”
3-9-16 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO SK: “Peregrine remains a strong company with a valuable clinical asset and a rapidly growing biomfg. business... We believe our relationships with AstraZeneca, Mem. Sloan Kettering, UTSW, & NCCN will be invaluable as we establish & execute our overall strategy for advancing the bavituximab I-O combination plans in a range of cancers.”
3-7-16: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs)
2-25-16: IDMC Halts Ph.3/NSCLC SUNRISE Trial at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations”
1-18-16: CEO Steve King's 1-18-16 presentation at Noble-Financial's Investor Conf. (21min replay, 31 slides)
1-11-16: Update on 4 New Bavi Clinical Trials (Lung/AZN, Breast/1Co./1MSKCC, Other Cancers/AZN). SUNRISE est's: Look1=Early'16, Look2=Mid'16, FinalUnblind=End'16
1-6-16: Peregrine enters into Research Collab. with Natl-Comprehensive-Cancer-Network (NCCN)
...$2mm res. grant to NCCN's Oncology Res. Pgm (ORP), will “significantly expand our clinical evaluation of Bavi and augment Peregrine's IST pgm at 26 of the world's leading cancer centers”.
12-10-15 Qtly. Conf. Call (King/Shan/Worsley/Garnick/Lytle) Transcript
...CEO SK: “Although our SUNRISE enrollment milestone has been reached, we have no intention of slowing down, quite the opposite. We are aggressively moving to initiate new clinical trials [Lung, Breast, Mult-Types] that will allow us to build the most robust oncology business possible… With each of these studies our goal is the same - we are committed to identifying key indications, patient populations, and therapeutics that can benefit from combination treatment with bavituximab. From what we have seen to-date, the opportunity appears vast and we are hard at work converting the most promising prospects into true value.”
10-15-15 Peregrine's ASM: ATTENDEE Reports & Link to SK's 18min/16slide webcast:
10-15-15: Peregrine & AstraZeneca Expand Collab. w/Ph2/2ndLine-NSCLC Trial, Bavi+durvalumab(MEDI4736), squamous or non-squamous.
9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”
8-24-15: AstraZeneca & Peregrine Collaborate on Bavi+Durvalumab Ph1/1B Trial for “multiple solid tumors”
...Durvalumab=MEDI4736(anti-PD-L1 immune checkpoint inhibitor). AZN’s Head/I-O(Robert Iannone): “Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."
7-14-15 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos”
3-12-15 Qtly. Conf. Call (King/Garnick/Shan/Hutchins/Lytle) Transcript   
...CEO S.King: “Bavituximab represents the most clinically advanced agents that target the immunosuppressive PS signaling pathway, and we are driven to bring this product to the market and believe it has the potential to help change the way cancer patients are treated. Our Ph.3 SUNRISE NSCLC trial continues to make great progress & is on track to complete enrollment in the study by YrEnd’15.”
3-9-15: CEO Steve King’s 24min. talk at ROTH Conf. (DanaPT CA) - SLIDES 
12-10-14 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...CEO S.King: “We believe Peregrine is in a unique position with an immune-oncology program already in Phase III, with what has been a positive safety profile and a target that is ideal for combining with other IO agents.”
10-16-14 Peregrine's ASM: Slides(42), Audio-Replay-Link, Attendee-Reports
9-9-14 Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript
...CEO S.King: “In addition to our clinical trials, many of which have also have translational data points built in to tie together pre-clin. data with the clinic, we have also continued to build momentum in our pre-clin. collaborations which now number in the dozens. We are evaluating new combinations & dosing strategies combining bavituximab with chemotherapy, radiation, and immune-oncology approaches, including those targeting CTLA-4, PD-1, as well as other downstream immune checkpoints."
7-14-14 Qtly. Conf. Call (King/Shan/Hutchins/Worsley/Lytle) Transcript
...CEO S.King: “Partnering remains a priority with the goal being to use partnerships to continue expanding the bavituximab program, while we continue to execute the SUNRISE Phase III trial.” 
3-10-14: CEO Steve King’s 22min. talk at ROTH Conf. (DanaPT CA) - SLIDES
3-7-14 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...CEO S.King: “I don't want to overuse the word ‘excitement’, but these are truly exciting times that have positioned us for success on all fronts.” 
12-10-13 Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Worsley/Lytle) Transcript
...With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone, Hakan Mellstedt
...CEO S.King: “We believe that Peregrine is uniquely positioned among the companies developing immunotherapies… and that because of our current valuation, we represent a unique investment opportunity.” 
11-2013: Stephen Worsley joins Peregrine as VP of Bus.Dev. 
11-12-13: CEO Steve King's 23min. talk at Credit-Suisse Conf. (Scottsdale) 
9-9-13 Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript
...CEO S.King: “In addition to the immunotherapy research, there has been significant interest in the results presented at ASCO showing an 84% tumor response rate in HER2- breast cancer patients.”
8-14-13: CEO Steve King's 26min. talk at Wedbush/NYC - SK. "We have very active partnering discussions [ongoing] around our 2 lead programs.”
7-11-13 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...CEO S.King: “This [new bavi] moa insight has opened the door to completely new combinations not previously explored.  Bavi acts on an upstream immune checkpoint, and thus, makes a potentially ideal combination with downstream-acting immune checkpoint inhibitors such as anti PD1 antibodies & CTLA-4 targeted approaches…  Preclinical studies are well underway to explore these combinations, and we look forward to generating and reporting data later this year that could support moving these concepts into the clinic.”
6-27-13: Updates on Bavituximab Pgm. & Cash Position
…“primary focus remains on the init. of the PhIII trial in 2nd-Line NSCLC by y/e; recent data supporting an immunotherapy moa for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents…"
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)  
3-18-13: CEO Steve King's 27min. talk at Roth Conf.(DanaPT CA) - Excerpts & SLIDES  
…CEO S.King: "Our goal is to initiate the Phase III trial (2ndLine NSCLC) by the end of 2013."
3-12-13 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript   
...Rob Garnick (Head/Reg.): "Re: 2nd-Line NSCLC: …the 3rd piece, which is important, is the efficacy piece, and as I point out to many people, there are very few and far between Phase II trials that ever show statistical significance in efficacy - that's an absolutely unbelievable hurdle for a Phase II product.  And, what you're really looking for is an ability to describe that you do have clinical efficacy, and as Joe has said, showing 11.7 mos. for the 3mg arm and a difference in the pooled dataset for the product of 7.3 mos. when you combine the control & the placebo, definitely gives you the indication that in overall survival, we have a potentially highly efficacious product… we're going to discuss the entire situation of the investigation with the agency, as well as all the data I just described, and we feel pretty confident that we have enough data to move the product effectively into Phase III."
3-5-13: CEO Steve King's 24min. talk at Cowen HC Conf.(Boston) - Excepts & SLIDES
12-10-12 Qtly. Conf. Call (King/Garnick/Shan/Lytle) Transcript
...CEO Steve King: "The goal of this (2nd-Line NSCLC ) review is to be able to generate a final data set that we believe could be used in discussions with the FDA to support advancing the program into a pivotal trial. Our partnering phase for Bavi has not changed. The partnering discussions are still ongoing, with potential partners remaining engaged, and like all of us, awaiting the outcome from this review…"
...Rob Garnick (Head/Reg.): "(Re: Cotara FDA-Approved Ph3 Design), we're pivoting right now and following the discussions with the FDA to discuss the same trial design plan with the Eur. agency and as well as potentially other global regulatory authorities. So, it's going to take a lot of effort and a lot of time, but we're very confident that we're going to be able to come up with one unified trial that will accomplish all of our goals."

10-17-12: Corp-Update ($14.3mm/ATM, Avid, Mult-Milestones, ASM Webcast Oct18)
…PDF of 10-18-12 ASM Presentation/S.King (19 slides), Attendee Reports:  
9-24-12: Peregrine sues CSM Over Bavi Ph.2B 2nd-Line NSCLC Clinical Trial Mix-Up
…CSM = Clinical Supplies Management Inc., Fargo ND
9-25-12: Peregrine Pays Off $15mm Loan from Oxford, triggered by 3rd-party data error:
……"we will have sufficient capital to fund our operations into Q4'13 based on current projections."
...8-30-12: $30mm Loan ($15mm/immed, $15mm/option) from Oxford Fin. 8K:
9-2012 PPHM's 2012 Annual Report: Theme => "Transformation"
9-10-12 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...CEO Steve King: "These are truly remarkable results that are not only great for the pgm… but also great news for the NSCLC patients in the trial…"
...Rob Garnick (Head/Reg.): "The NSCLC data we announced 9-7-12 has far exceeded our expectations, and I hope that you're as excited as I am with bavituximab's potential. I feel strongly that Peregrine should be recognized for having the corporate courage to conduct the rigorous, randomized placebo-controlled Phase II trial that provided these robust data and that provide the basis for us to plan for a pivotal Phase III program.."
...CFO Paul Lytle: "As you can imagine, given the Bavi results that we shared with you on Friday [9-7-12 2nd-Line NSCLC], our partnering activities are continuing at a very active pace as we move closer towards the EOP2 meeting with the FDA. Our stated goal is to have a partner on board before we start the Phase III trial and, preferably, before the EOP2 meeting with the FDA, as we would like our future partner to be a part of that important meeting." 

9-5-12: CEO Steve King's 26min. talk at Stifel-Nicolaus/Boston
8-30-12: $30mm Term-Loan Secured ($15mm/immed, $15mm/option) + 273k 6yr warrants@2.47 8K:
8-15-12: CEO Steve King's 29min. talk at Wedbush/NYC
…SK: "As we're sitting here today, we have still not reached MOS in either of the Bavi arms in the 2nd-Line NSCLC trial - and, in fact, we still have patients that are on treatments."  Q&A: "it's going to be a very positive MOS result, it's just a matter now of magnitude. We've laid out our strategy for financing the company; we've not been raising money thru the capital markets in any way.  We're not currently planning on going out for, nor have we been actively involved in any other fund-raising activities.  Right now, our stated goal is to pursue a debt-arrangement - with an asset like Avid Bioservices, we can get very preferential rates on raising debt-type funding right now, which we feel is the least-dilutive for the company."
7-16-12 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
...Steve King: "The strength of this 2nd-Line NSCLC data (esp. MOS trends) in this large area of high unmet medical need has also sparked a surge in partnering discussions that has included over 15 in-person partnering meetings since that time with major players in oncology, with all discussions ongoing and addl. parties showing interest. Our goal for the program is to position ourselves, along with a potential partner, to initiate Ph3 by mid-2013, which means an EOP2 meeting by yr-end'12. It would be ideal to have a partner on board to participate in the EOP2 meeting, and we have communicated this to interested parties and they agree."
Robert Garnick: "We've been working very hard and very actively on the next steps in our Bavi 2nd-Line NSCLC pgm, given the favorable data that we've seen. As you can imagine, with data like this, there are many things that we need to consider. One consideration is that, should the data continue to trend the way it is, particularly in survival, this opens a door for potential discussions around a pathway for ACCELERATED APPROVAL. At this point, all options are being considered, with Peregrine working towards the most efficient path forward from a regulatory standpoint." Q&A: "…all in all, I think the data is extremely compelling and I think it makes a really good case. Certainly, I think, I've seen a lot of Ph2 & Ph3 data, and this is as compelling Ph2 data as I've ever seen. So, I'm very comfortable proposing a meeting with the FDA for Q4'12."
7-12-12: CEO Steve King's 26min. talk at JMP/NYC
…SK: "Re: 2L/NSCLC trial, the most thrilling thing is the fact that, even though we had reached the MOS by the cutoff point at the end of April of less than 6mos. for the Doce ctl-arm, the majority of patients are still alive in both Bavi arms, and we expect that to continue for some period of time still."
6-20-12: PPHM hires Securities, Financing, and M&A Attorney Mark Ziebell as VP, General Counsel
3-12-12: CEO Steve King's 24min. talk at ROTH-OC(DanaPT)
…SK: "I think the best-case result is, if we have just phenomenal results out of this study (2ndLine-NSCLC), that we would obviously talk to the FDA about Accelerated Approval; that was our intention to begin with."
3-9-12 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript
…Rob Garnick, "re: 1st-Line NSCLC, I personally don't read a lot into ORR data nor PFS and really go for the std. that really counts that's unequivocal & relatively straightforward to measure, which is MOS, and I think we have to wait for those results in order to make any judgment. And on top of that, I'd like to point out that our primary goal is in 2nd-line NSCLC, which is a disease with very low response rates in general (10% or 11%), and what we're expecting to show there is a real increase ultimately in survival. And, if we see that, that's what we'll take forward into a Phase III pivotal trial."
2-14-12: CEO Steve King's 24min. talk at BIO-CEO/2012 (NYC) - slides & excerpts
…SK: "Our pipeline is completely unencumbered, so as we look into 2012 & beyond, we think we can bring in significant monies thru partnering deals which will help us move the programs forward."
12-12-11 Qtly. Conf. Call (King/Shan/Lytle) Transcript
…SK, "Our goal is to secure regional partners for our Bavi oncology program, and we look forward to seeing addl. data points from our randomized trials as we advance these discussions. [re: Cotara/GBM Ph3], the FDA has agreed to provide specific feedback to us in writing on our proposed pivotal trial design that we submitted to them."
9-27-11: JMP Securities Healthcare Conf./NYC - SK's Slideshow Capture
9-9-11 Qtly. Conf. Call (King/Garnick/Shan/Lytle) Transcript
...Robert Garnick: "As we saw over the last couple of weeks, the most recently approved therapy for NSCLC drugs (Pfizer's crizotinib=Xalkori) can in fact receive Accelerated Approval based on ORR data gen'd from single-arm studies, and we're very eager to assess bavituximab's potential in our ongoing trials."
9-8-11: CEO Steve King presents at Stifel Nicolaus HC/Boston - a few slides, incl. milestones:
7-14-11 Qtly. Conf. Call (King/Shan/Garnick/Masten/Eso/Lytle) Transcript
...Robert Garnick: "It's really easier to approach regulatory agencies with promising survival data and a consistent safety profile, which is exactly what we have seen from both bavituximab & Cotara in our clinical trials to date."
6-29-11 Minyanville article, "Peregrine Pharma's Secret Weapon [Robert Garnick]"
…CEO Steve King considers his company fortunate to have someone with Garnick's long history with the FDA. "Rob is the ringmaster," King says.
11-8-11: April Loui (ex-Genentech Sr.Mgr/QA) joins Peregrine as Director/QA
5-31-11: Jeff Masten (ex-Genentech Sr.Dir. of Quality) joins Peregrine as VP/Quality
..."This is an exciting time to join Peregrine, as bavituximab advances through numerous Phase II clinical trials and Cotara's registrational path is being outlined. I look forward to working with CEO Steve King, head of regulatory affairs Rob Garnick, and the extended teams at Peregrine and Avid to drive industry-leading quality programs and facilitate regulatory agency inspections as we support Avid's third-party clients and prepare for potential launch of Peregrine's products."
5-26-11: Dr. Steven Chamow (ex-Genentech) joins Peregrine as Head of Process Science
5-19-11: Nuclear-Med. & Oncology Specialist Dr. Vladimir Evilevitch (ex-Parexel, ex-Novartis) joins PPHM as Med.Director
…"to execute Cotara Regulatory & Clinical strategy"
4-2011: Peregrine adds 2 more "Regulatory" people, Kathryn Hansen (ex-Amgen) & Soheila Dadgostari (ex-Valeant)
3-14-11: S.King at Roth-OC/DanaPT - slides & excerpts:
...SK: "Cotara/GBM Ph.2/40pt enrollment completed in Dec'10; expect top-line by mid'11, We've already begun preparing for an FDA meeting in 2H'11, in which the goal is to get an SPA ("Special Protocol Assessment") approved; at that point, the drug is highly partnerable." [Per David Miller, "the idea is if you sign an SPA with the FDA and conduct the trial as agreed, good results from the trial will be sufficient for marketing approval."]
3-11-11 Qtly. Conf. Call (King/Shan/Thorpe/Lytle) Transcript
3-9-11: Dr. Kerstin B. Menander (ex-Abbott) appointed Head of Medical Oncology
3-4-11: Reuters' Deena Beasley Interviews Steve King
...SK: "The study [ongoing Ph.2b Bavi+Doce/Refract-NSCLC] could provide the basis for seeking U.S. regulatory approval… This is easily a $1B+ potential drug in NSCLC alone."
12-9-10 Qtly. Conf. Call (King/Shan/Eso/Lytle) Transcript
…S.King: "our next planned virus therapy trial will evaluate Bavi+Ribavirin vs. HCV patients… we are planning to initiate addl. Co-sponsored trials & ISTs in the very near future."
11-2-10: Peregrine Awarded $977,917 Therapeutic Discovery Grant
10-21-10: Carlton Johnson appointed Chairman of BOD & SHM Results
10-3-10/OCBJ: PPHM Repeats as #1 Growth Co. in OrangeCo.
...Last-12mos-Rev: $27.9mm, 3yr-Sales-Growth: +358.6%
9-13-10, CEO S.King, R&R/NYC:
…S.King re:TMT: "We're at the point where we're getting into more advanced models of the disease, as well as starting to look at some combination-therapy potential of the drug. The plan now is to complete that evaluation, to firmly establish that pgm going forward - then at that point it'll be a contract modification, and from everything we hear, we s/b moving fwd with addl. animal studies."
9-9-10 Qtly. Conf. Call (King/Eso/Lytle) Transcript
…S.King: "[On the AV side], so far every type of virus we have looked at does induce PS exposure on infected cells. And that creates a vast number of opportunities, everything from immunocytokines, which we're currently evaluating as part of our UC Discovery grant work, all the way to targeting nanoparticles, in which you could basically take these nanoparticles, load them with different antivirals depending on the particular type of antiviral indication, and specifically deliver your drugs to the infected cells, reducing the toxicity of the agent and taking advantage of our technology platform. And, there's actually interest in all of those from both funding agencies as well as potential partners down the road. So, I think there's a lot of great utility of that technology platform and the group here is looking at a number of different areas that we really think have pretty dramatic potential from a market standpoint, but also just can build & build on what really is a platform that has so much utility."
9-7-10 PS Patents Granted: 7790860/Imaging 7790159/Antiviral
8-2010/IF LINKEDIN IS RIGHT: Dr. Shelley Suggett (ex-Genentech Sr.Product.Dir/Regulatory) joins PPHM as Director, Regulatory Affairs
7-14-10 Qtly. Conf. Call (King/Garnick/Shan/Eso/Lytle) Transcript
…Robert Garnick: "I like to end by again saying how optimistic I am about bavituximab's potential. The growing body of research points to bavituximab potentially providing a unique & valuable new approach for the treatment of cancer. The clinical results we have to date support moving forward with our regulatory strategy to advance this novel antibody."
6-14-10: PPHM set to join Russell 3000 - reconstitution occurs 6-28-10:
6-9-10 CFO Paul Lytle's 26min. talk at Needham HealthCare Conf./NYC
...See slide5: considerable discussion of possible addl. Gov't Contracts & Grants, like new IRS "Therapeutic Discovery Proj. Pgm" (max=$5mm).
5-18-10: CEO Steve King's 20min. talk at R&R HealthcareConf/London
…SK: "based on these [Bavi Ph.2] clinical data and our interactions with the FDA, we're in the process of operationalizing a Phase IIb Registrational Trial [Bavi+Doce 2nd-line NSCLC]. We're referring to this as a "registrational trial" because one potential is if we anywhere close to approximate the results we've seen in a prior study, this could be an opening for Accelerated Product Approval."
3-17-10: CEO Steve King's 23min. talk at ROTH Stock Conf. (DanaPT CA)
…SK: "And then we have a real interesting part of the portfolio, which is our Bavi VHF pgm. This is completely funded by the DOD… evaluating Bavi for the treatment or prevention of VHF. What's interesting about this compound is this would not take a typical Phase1-2-3 approval approach, but rather likely go thru the FDA's "Animal Rule", which means that it basically would have animal efficacy data, combined with human safety data, which we're obviously generating a lot of, and then it would be applied for approval based on those 2 things. So this could be a much shorter entry point into an actual product that could be acquired by the gov't to stockpile as part of its biodefense efforts."
3-11-10 Qtly. Conf. Call (King/Lytle/Shan/Eso) Transcript
…SK (resp. to Joe Pantginis question re: strategy for Bavi): "Clearly there is a lot of interest in the bavituximab pgm - novel monoclonal antibody therapies with an interesting target that has broad-spectrum capabilities in multiple indications - clearly there are not a lot of those out there… we have a lot of interested parties; we will continue to keep those potential partners updated on our clinical trial progress."
2-9-10: CEO Steve King's 23min. talk at BIO-CEO/2010 (NYC)
…SK: "what we're most intrigued about is Bavi's potential in Refractory Disease, which of course is the fastest route to product approval."
1-13-10: CEO Steve King's 16min. talk at OneMedForum2010 (SanFran)
…SK: "The [next] study we have discussed with the FDA is Bavi+Doce in 2nd-line NSCLC. In this patient population, they have about a 6% resp. rate; so, a high unmet medical need, and we think an excellent opportunity for development. The trial design we've agreed to with the FDA is essentially a registrational Ph.2 design; it's going to be about a 120 patient study, double-blinded, placebo-controlled… the goal being, if we see positive results & excellent results, that we really want to be able to take advantage of that and potentially approach the agency about Accelerated Approval."
1-11-10: Dr. Marvin Garovoy (Ex-XOMA VP) joins PPHM as Head/Clin.Science
…Dr. Garovoy will have primary responsibility for establishing & supervising an Investigator-Sponsored Trials (IST) pgm, as well as expanding scientific outreach & assisting with clinical trial design for the Bavi & Cotara pgms.
…CEO SK: "These ISTs can be a very important part of our overall clinical dev. pgm, potentially providing invaluable info. that might not otherwise be obtained from our company-initiated trials."
…Dr. Garovoy, "Bavituximab is a promising new approach with broad potential for the treatment of solid cancers and other diseases. Based on the encouraging results seen in early clinical trials, I welcome the opportunity to collaborate with clinical researchers to establish the investigator-sponsored studies that will enhance our understanding of the clinical potential of this exciting new agent."

ARTICLES, ANNUAL SHM'S, & CC'S - Archive 2005-2009:

BAVITUXIMAB ANTI-CANCER NEWS (see above for Trials Info):
4-4-17: AACR'17: 5 posters, incl. new 2nd MSKCC/Wolchok Bavi+ACT study -
4-20-16 AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active”
6-1-15 ASCO’15: 3 Bavi/AntiPS Posters (NSCLC, Melanoma, Breast, Liver) & Plans to add Ph2/3 Bavi Trials (NSCLC/Optivo, Her2- Breast)
4-20-15 AACR’15: 3 Abstracts/2 PR’s - Bavi Clinical TransData/Lung & PreClinData/Melanoma/Breast – Moffitt/S.Antonia, UTSW/R.Brekken, UC-Irvine/CW.Hughes, Peregrine
4-2014 AACR'14: Peregrine's 3 preclin. posters 
...about Bavi as an “Upstream PS Checkpoint Inhibitor”; notably, “when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates an improved protective tumor-specific immunity following tumor rechallenge”, and, “combination of bavituximab with the anti-PD-1 checkpoint blockade should synergistically induce potent long-lasting antitumor immunity.”
4-2013 AACR'13: Peregrine's 3 preclin. posters
..."data on the immune stimulating moa of Bavi, anti-tumor & imaging potential of other PS-targeting constructs"
10-31-12, New PS-Targeting Preclin. Data - Mabs Stimulate Cancer-Fighting Immune Responses & Specifically Target Tumors
…10-25-12 SITC Poster describes Bavi's 3-pronged MOA, and 10-10-12 Nuclear Medicine & Biology article on "ImmunoPET Imaging of PS" using 89Zr-PGN635.
8-2-12: Texas CPRIT grants Philip Thorpe $1.4mm in $4.1mm Lung Cancer Project (SRBT/Rad+AntiPS)
. . .Dr. Thorpe's Project4 "Lay Summary" =>
5-1-12 Audio replays of the NYAS Anti-PS Symposium (NYC) now at
…The 5 Speakers were: Alan Schroit, David Ucker, Ari Helenius, Chris Reutelingsperger, Philip Thorpe => Dr.Thorpe's 46min talk:  
4-2012: UPenn & Dr.Thorpe Neoplasia article on PGN635 vs. Lung Cancer
…on the potential benefits of treating with fhBavi+Chemo (PGN635+cis) AFTER Surgery - an approach offering "significant promise to prevent lung cancer recurrences."; also contrasts Bavi vs. Avastin on side effects.
4-2012 AACR'12: 7 Posters (3 Bavi/IST's, 3 Bavi/antiPS pre-clin, 1 TNT-Imaging) (see #2452)
…Peregrine Launches PS-Targeting Clinical Imaging Pgm. (fully-human 124I-PGN650), IND recently filed.
8-2011: Gerber/Thorpe IMMUNOTHERAPY article on Bavi+Chemo/NSCLC
...Obviously resulting from: 6-10-09 ASCO $200k Grant to UTSW's David Gerber for New Bavi/NSCLC Study:
6-2011 Dr. Philip Thorpe article in VACCINE on the "Anti-PS Fusion Protein" 2aG4-IL2:
…"Enhancing The Potency of a Whole-Cell Breast Cancer Vaccine in Mice with an Antibody-IL-2 Immunocytokine that Targets Exposed PS"
5-26-11: Dr. Philip Thorpe Keynotes Bavi/PS MOA at Recombinant-Antibodies Conf. in Barcelona
…Dr. Thorpe, "What is especially exciting is that administration of PS-targeting antibodies like bavituximab breaks the grip of the tumor on the immune system."
...A few of the more illustrative slides from Dr. Thorpe's 5-26-11 talk: . . .PT's entire 53-pg PDF:
4-5-11 AACR'11 #3643: Sorafenib Enhances Anti-tumor Effects of Bavi in Liver Cancer (HCC)
…Dr.Thorpe: "These data suggest that the growth-blocking mechanisms of sorafenib combined with the vascular-targeting & immune-reactivation mechanisms of bavituximab may offer additive anti-tumor effects for patients with HCC."
4-6-11 AACR'11: Peregrine's 4 PS-Targeting Presentations
…#621/ADT-Prostate, #3651/AntiPS-MOA, #3643/Sorafenib-Liver, #4880/FH-Bavi-Imaging
3-24-11: Phil Thorpe, E.Ward, R.Ober, R.Mason awarded $6.0mm by Texas CPRIT &
…"to develop a new class of [Anti-PS] therapeutics to treat cancers involving the brain & nervous systems, breast, liver, interhepatic bile duct, lung, bronchs, and prostate."
...…8-2011: UTSW Article about 3-2011 $6.0mm CPRIT Award to Thorpe/etal for AntiPS dev.
......11-2011: UT-Dallas Article about Dr. Raimund Ober's role in 3-2011 $6.0mm CPRIT Award for AntiPS dev.
12-1-10: Dr. Phil Thorpe co-author of J.Clin.Investigation article about "novel therapies" for APS thrombus issues
…APS (antiphospholipid syndrome) can cause life-threatening clotting disorders. One of the mabs tested was 2aG4 (mouse model of Bavi).
4-12-10: IST program (Investigator Sponsored Trials) launched: & PeregrineInc/IST's
AACR'10 #1919 4-19-10: PS-Targeting Mabs Can Reverse Tumor-Induced Immune Suppression
…Dr. Thorpe, "This study shows that the immunosuppressive effects of PS exposed on apoptotic tumor cells can be reversed by PS-targeting antibodies, specifically by reversing the suppression of DC maturation caused by the exposed PS. This finding is important since reactivation of the immune system after the primary tumor has been removed is a critical line of defense in fighting cancer recurrence. Additionally, we showed that PS-targeting antibodies have the ability to confer tumor-specific immunity, which could lead to the future development of new cancer vaccine regimens."
4-21-10, AACR'10, 3 Wed. Posters (#5337,5330,5232)

5-25-16/OncoTarget, “PS-Targeted Liposome [PGN635=Fhu-Bavi] For Enhanced Glioma-Selective Imaging” - Wake Forest's Dawen Zhao & UTSW's Liang Zhang
6-2014: Two Bavi-Imaging abstracts by UTSW at Society of Nuclear Med+Molecular Imaging (SNMMI) Annual Mtg
11-26-13: PGN635 (Fhu-Bavi) Imaging article in Molecules2013 by UTSW’s Liang Zhang & Dawen Zhao
12-19-13/PLOS/Philip Thorpe: “Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets PS”
10-31-12, New PS-Targeting Preclin. Data - Mabs Stimulate Cancer-Fighting Immune Responses & Specifically Target Tumors
…10-25-12 SITC Poster on Bavi's MOA, and 10-10-12 NMBA article on "ImmunoPET Imaging of PS" using 89Zr-PGN635 (see Genentech below)
10-12-12: Genentech studying Imaging using PGN635(Fhu-Bavi) for the potential "detection of tumor response to therapy".
Nuclear Medicine & Biology, Genentech's Jan Marik, "ImmunoPET Imaging of PS in Pro-Apoptotic Therapy Treated Tumor Models"
4-3-12: Peregrine Launches PS-Targeting Clinical Imaging Program (AACR'12 #2452) &
…PPHM "recently filed an IND" with FDA for an Imaging trial using 124I-PGN650, ~12pts.
...6-28-12: Trial added to - see CANCER TRIALS ABOVE for more details.
12-2011: Thorpe Article on FH-Bavi/Optical-Imaging in Translational Oncology
11-14-11: Dr. Bruce Freimark presents PS IMAGING poster at AACR-NCI-EORTC Conf./SanFran
9-12-11: Drs. Thorpe & Freimark present PS IMAGING posters at World Imaging Congress/S.Diego
9-9-11: PS IMAGING potential discussed in Qtly. Conf. Call:
4-2011/Neoplasia: Dr. Thorpe 9-pg. article on Exposed-PE/Imaging
…Dr. Thorpe: "PE also has potential as a marker for Imaging human malignancies."
4-6-11/AACR'11: Tumor Imaging Applications of PS-Targeting Antibodies
…Steve King: "Molecular imaging is a growing field and represents an entirely new development opportunity for our first-in-class PS-targeting antibody platform… our antibodies labeled with imaging tracers hold potential for illustrating exposed PS in a clinical oncology setting, imaging PS as a companion diagnostic with bavituximab therapy, as well as ultimately assessing patient response to a range of cancer therapies."
3-14-11: Dr. Thorpe discusses PS IMAGING in Conf. Call:
…Dr. Thorpe: "The quality of the images is quite extraordinary. The antibody homes to tumor blood vessels beautifully in all tumors that we've seen with really very, very little of a staining seen in other tissues, and that's just what you'd like to see in a diagnostic - we are looking at that very seriously. And also, that binding is correlated to response, both with radiotherapy & chemotherapy. So again, we have the possibility of making a diagnostic that would be predictive of response. We are evaluating that possibility at this time... Duramycin binds PE; binding PE expands our coverage of our broad aminophospholipid-targeting platform, so it really dovetails very beautifully with the existing antibody portfolios. It's expanding our desire to explore different phospholipids as potential targets for therapy & diagnosis… PE is phosphatidylethanolamine and it is the brother of PS. So where PE goes, so does PS and vice versa. So the 2 lipids co-segregate normally on the inside surface of the plasma membrane, but in activated cells or apoptotic cells or stress cells, both lipids flip, and both are potential targets for therapeutics or diagnostics… Duramycin is a little peptide, that's a small molecule and has quite different qualities from an antibody in terms of penetrants. So we're intrigued to see how it plays out, too."
6-24-09 U.S. Patent #7,550,141 granted: Anti-PS for Tumor Imaging:
3-3-08: Thorpe/Mason C.C.R. (AACR) article on Arsenic-labeled Bavi for Imaging Tumors:
…3-5-08 Chemistry World followup article on CCR Bavi+Arsenic/IMAGING:
2006/SMI: Thorpe/Mason, "Optical Imaging of Exposed PS in Tumors"
…"We believe optical imaging with Bavituximab holds great promise for assessing PS expression, and therapeutic activity in vivo and optimizing treatment protocols."

11-1-15-UTSW/Mayo/Tulane/PRC: “PS-Targeting Mabs Inhibit Choroidal Angiogenesis InVivo & ExVivo” [CNV/Macular Degen]
5-2012: Two Anti-PS (PGN632 + PGN635) Ocular posters at ARVO'12 Annual Mtg./FtLaud
..5-6-12/Thorpe+Mayo, "Anti-PS (PGN632 & PGN635) as Potential New Therapy Against Choroidal Neovascularization (CNV) - AMD"
..5-10-12/PPHM+LSU, "Efficacious Clinical Outcome of an Ophthalmic Formulation of PS-binding mab (PGN632) in a Rabbit Model of Acute HSV-1 Keratitis"

BIOSIMILARS INITIATIVE - History & Update thru 9-9-10 CC: (S.King, 9-9-10, "we're currently evaluating a number of different potential targets to go after.")
12-8-10: Avid signs Biosimilars Services Deal with USA/China firm:

I: THE 2008-2011 DTRA/TMT Gov't Contract for Anti-PS vs. Hemorrhagic Fevers
3-11-11: TMT/DTRA will not extend VHF Contract - expires 3-15-11 (total revs. rec'd=$24.2mm):
…Steve King (3-11-11 CC): "While this news is certainly disappointing, we are grateful to the TMT & DTRA for the opportunity to work together to evaluate bavituximab in this unique potential indication. We received nearly $24mm in funding over the past 33 mos… In the studies we have conducted to date under this contract, our antibodies have demonstrated a significant increase in survival in advanced preclinical models of the highly lethal Ebola virus. However in these specific studies, we weren't able to achieve an adequate dose response correlation to support advancing the program to the next stage. In no way does this dampen our enthusiasm for bavituximab and the PS-targeting platform for infectious diseases, where we believe there is still significant unrealized potential."
11-16-11: Two AntiPS posters presented at DTRA's 2011 CBD S&T/Vegas
...1) Argentine Hemorrhagic Fever/UTexas. . .2) Bacteria Infections/DSTL Porton Down/UK & Thorpe/King/C.Empig/PPHM
11-16-10: PPHM Presents AntiPS/VHFs pre-clin. data at CBDS&T BioDef Conf./Orlando
10-2009: U-Pitt report for DARPA on Biologics Demand references Bavi
11-18-09: PPHM Presents AntiPS/VHFs pre-clin. data at DTRA/TMT Conf.
7-3-08 BioWorld Today article on PPHM's DTRA Deal:
Duke's B.Haynes CAVD-Reports outline Thorpe's Role in the CAVD-Gates HIV-Vaccine Initiative:
…"Philip Thorpe is determining the role of lipid binding of anti-HIV antibodies and anti-phosphatidylserine (PS) autoantibodies to protection from HIV infection."
3-2014: Keystone Conf./Alberta PS-Targeting/HIV Poster by PPHM’s Cyril Empig & Duke/Peregrine Co-Authors Haynes/Moody/etc
…”We expanded the characterization of PGN632 in the current study; PGN631 & PGN633, “sister clones” of PGN632, are also able to inhibit HIV-1 in the PBMC assay.”
12-29-11: Duke patent app#20110318360 "Anti-Lipid Antibodies" describes using PGN632 to inhibit HIV infection
Sept'10: LWW article by Barton Haynes ref's 4-2010 Duke/PPHM JEM antiPS article:
......"HIV vaccines after STEP: Strategies for Eliciting HIV-1 Inhibitory Antibodies"
4-11-10: CHAVI Newsletter highlights PPHM-Duke JEM article
..."The study is significant because it shows that components of the adaptive immune system can activate antiviral innate immunity. Investigators believe that a vaccine that elicits polyreactive anti-PS antibodies could potentially be used to engage both the innate and adaptive immune response against HIV."
4-5-10: DukeHealth announces the 1st Duke/PPHM HIV Collab. article in JEM:
...Duke's Bart Haynes: "While the findings still have to be tested clinically, they do suggest a new way the immune system might be manipulated to thwart HIV."
...The full 4-5-10 JEM Duke-PPHM HIV article (23pgs) posted to PPHM's homepage:
2005-July2009: All Peregrine Public Statements on the Duke HIV Collab:
10-14-08: "The AIDS Vaccine 2008 Conference", CapeTown, So.Africa
...Duke's B.Haynes & T.Moody present Anti-PS data for 1st time publicly: "The most potent mAb, PGN632 [11.31], inhibited 7/7 B & C clade HIV-1 isolates & SHIV SP162P3... Studies showed the mAbs acted at host cell surfaces to inhibit HIV-1 infection."
...Dr. Ralph Pantophlet's summary of T.Moody's Talk, incl. two PGN632=11.31 test data graphs:
.....1-6-09: NIAID reviews CapeTown AIDS'08, commenting on the Tony Moody Anti-Lipids/PGN632 talk:
10-15-14: Public-Health-England/PPHM article on Bavi/Ebola in Hindawi’s Jrnl-of-Immunology-Res (also see: )
6-2013: NIAID is “particularly interested how PS & PE expression… which is key to regulation of the immune response.”
…the above from John Coligan’s (PhD, Chief, Receptor Cell Biology Section) NIAID lab webpage.
11-16-12: 'Antiviral-Research' article by Bavi-AV collaborator HPA/UK & PPHM researchers on Bavi vs. EBOLA
…"Virus induced externalization of PS raises the possibility that PGN401 (Bavi) has broad spectrum antiviral activity."
11-16-12: 'Parasite Immunology' article by Dr. Phillip Thorpe & Brazilian Bavi-AV collaborators on AntiPS vs. Leishmania
..." This study provides new information regarding the mechanism of immune suppression in Leishmania infection."
8-2011: Brazilian collab's (INCA) studying PS-targeting vs. Leishmaniais, a protozoan parasitic disease
11-4-09: 2nd Patent (7,611,704) Granted for AntiPS Broad AV apps
..."noteworthy since it includes methods for treating all viruses in humans & animals."
10-7-09: PPHM forms 'Anti-Viral Research Group'
…"Peregrine's broad-spectrum PS-targeting antibodies are being assessed in anti-infective applications by more than a dozen leading research institutions… Peregrine and its collaborators have already secured over $60 million in research funding to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections…"
9-10-09: PPHM's 7 Anti-PS Collaborators (S.King, R&R Healthcare Conf/NYC)
8-26-09: $763k NIAID Grant to Dr. Thorpe to Expand Anti-PS/VHF Studies:
…"The objective of the newly funded research is to evaluate a panel of new fully human anti-PS antibodies with different binding & functional properties as potential 2nd-gen. treatments."
8-5-09: 'New Scientist' Article Highlights Peregrine/Thorpe/BaviAV
...Dr. Thorpe, "We were doing something that was quite extraordinary. We had let the animals progress in their disease until they were heavily symptomatic, and then started treatment. It was a major accomplishment to knock that disease back."
...7-11-09 Dr. Thorpe Interview on Bavi-AV in BMED Report:
3-31-09: 3rd (Conjugated) Anti-PE Patent (#7,511,124) Granted:
1-6-09: New 'Anti-PS Anti-viral Factsheet' on the PPHM Website:
11-24-08: Dr.Thorpe publishes in Dec.2008 NATURE Medicine on BaviAV vs. Lassa/CMV:
...Dr. Thorpe, "This is a whole new strategy for making antiviral drugs." . . . CEO S.King, "We think it has tremendous potential."
...Dr. B.Haynes, "Targeting a host cell lipid such as PS as an anti-viral strategy is an intriguing concept that may have relevance for new therapeutic and possibly prophylactic innovations in a number of virus infections."

Highlights of Cotara/GBM Trials History 1998-2009:
12-5-12: FDA OK's Ph3 Pivotal Trial Design for Cotara/GBM (single-infustion, dual catheters)
…SK: "We can now escalate our business development activities to secure a partnership, recognizing the great interest by companies in drug candidates within the orphan and rare disease space." 
5-3-10: PPHM Licenses TNT rights in "Certain APEC Countries" to STASON(Stonsa Biopharm)
Stonsa's website:
...Harry Fan/CEO/Stason, "This agreement represents a unique opportunity to acquire a novel, cutting-edge pharmaceutical technology package and bring innovative & promising treatments to millions of cancer patients in Asia & the Pacific Rim. We will also continue developing new applications & bioproducts based on TNT technologies to complement Peregrine's activities in the glioblastoma arena and will aggressively pursue new, diverse biotechnology markets. To advance these efforts, a new spin-off biopharmaceutical company (Stonsa Biopharm Inc.) headed by Dr. Eugene Mechetner will be formed which will focus on commercializing TNT technologies."
7-20-11: Dr. Missag Parseghian now VP/R&D at Stonsa Biopharm; pub's article in Jrnl/Chromatography
…6-2010: More on PPHM-Stason Collab., "TNT For Tumors", Lloyd Dunla, Drug Disc. News
…5-27-10: Stonsa's CEO Dr. Eugene Mechetner presents TNT at Taiwanese Bio-Seminar
...12-16-10: "Stason Inks Deal to use Lonza's GS Gene Expression System with TNT Antibody Platform"
7-1-09 Eur. Patent #1638989 for 'In-Line Labeling' (used in Cotara GBM trials) & JNM Article:
India (expanded Jan'10 to U.S.) Cotara/Brain Ph.2 Trial (40 patients, 1st relapse):
India's DCGI protocol (init=7-2007):
7-2011 BRIT (India Radiolabelling co.) says: "(Cotara) Ph2 completed; another order is expected from Peregrine to enable them to go ahead with Ph3"
10-11-11: SIRO Clinpharm is Peregrine's Indian CRO for GBM/Cotara Ph.2 Trial:
6-3-11 ASCO'11: Dr. William Shapiro (Barrow) presents Cotara N=41 Data
…"Interim MOS=8.8mos(38wks); we are eager to meet with the FDA in Q4'11 to determine the optimal registration pathway for Cotara."
...NOTE: In 12-12-2011 QtlyCC, S.King reported MOS at 9.3 mos., up from in "interim" 8.8mos reported at ASCO'11.

…Dr. Shapiro's Cotara Poster #2035 (PDF & Images)
5-19-11: ASCO'11 preview; Dr. Vladimir Evilevitch (ex-Novartis) hired as Med.Dir. "to execute Cotara Reg&Clin. strategy"
12-20-10: Treatment Complete in Cotara/GMB Ph.2 Trial
…J.Shan: "We expect top-line data by mid-year 2011 and plan to meet with the FDA to define the optimal registration pathway for Cotara."
10-18-10: Interim Ph.2 update (n=14) at CNS'10:
...PI Dr. Deepak Gupta, "MOS of 86 weeks far exceeded our expectations in this very difficult to treat patient pop. where treatment options are few and rarely extend med.survival beyond 6mos."
…Roth's Joe Pantginis: "Physicians know how long these patients are expected to survive on avg. and that's why these data are very, very promising. Because there is a huge unmet medical need for new treatments for this type of brain cancer, Peregrine may seek an accelerated approval that could avoid lengthy Phase III clinical trials."
...Link to Dr. Gupta's CNS'10 Poster (6pg PDF):
...6-3-10/ASCO: Cotara/Ph.2 Trial 75% enrolled; 3 more U.S. sites added:
...1-28-10 U.S. site (Barrow/Phoenix) added formerly India-Only Ph.2 trial:
…Per 3-11-10 QtlyCC, VP/ClinAffairs J.Shan said also exp. UPenn & Univ. of S.Car.
…9-2-09 Interim Ph.2 data (10 pts) presented at AANS Annual Mtg/Boston:
……P.I. Dr. A.K. Mahapatra: "Most importantly, Cotara has demonstrated promising signs of efficacy."
...8-2-07 1st Patient Dosed in Indian Cotara/Brain Ph.2 Trial:
...The obvious desire is to compare Cotara vs. SOC Temodar for GBM therapy:
USA Cotara/Brain 'Dosimetry & Dose Confirmation Trial' (originally funded by NABTT):
U.S.A. Cotara Brain Cancer trial protocol (added 8-14-07):
6-6-10/ASCO: Final Results of Cotara/GBM Ph.1/Dosimetry trial (n=12):
......"Final data confirm Cotara's targeting capabilities, delivering 300-fold higher radiation levels to the tumor than to normal organs."
...2-11-10: "Current Cancer Therapy Reviews" article on Cotara/GMB
......the cases of "2 patients who have survived more than 9 years" are also reviewed.
...12-2-09: U.S. Trial Enrollment Complete
...6-16-09: Cotara/Brain Oral-Pres. at SNM Annual Meeting
......Dr. Sui Shen (U-Alabama), "With a mean dose ratio showing 300-fold greater delivery of radiation to the tumor as compared to other organs, Cotara represents a potentially valuable new therapy for GBM patients."
…9-23-08: Article in Cleveland paper - comments by P.I. Dr. Andrew Sloan (Case Western/CLEV)
...5-31-08: Cotara USA Ph.1B data presented at ASCO/2008:
...8-29-05: NABTT Initiates Cotara/Brain Trial (28 patients/4 sites):
...Orig. NABTT protocol, "6-2007, completed":
...The Phil (Marfuta) Bannister Story (NABTT Cotara/GBM patient #1, diag. 2-4-06):
......4-22-10: Phil reports on YASG that his GBM was misdiagnosed; he has a GrIII Oligodendroglioma, which carries a MLE of 12yrs!
Previous USA Cotara/Brain Ph.1-2 Trials, completed in 2003:
...Slides showing correlation between Cotara dosage levels and MST vs. Temodar(curr.SOC):
...4-27-08 update: The Jerod Swan Cotara/Brain Success Story (10 years after diag.):
...5-22-07 update: The Freddie Sanford Cotara/Brain Success Story (7 years after diag.):
...6-1-05: Cotara w/CED Brain Delivery pub. in Neurosurgery Jrnl:
..."Cotara Holds Promise for Treating Brain Cancer - P1/P2 Data Suggests Extended Survival in a Number of Patients"
…12-13-01: FDA OK's Ph3 Design for Cotara/GBM (2 doses, single interstitial catheter)
…7-1-02: Peregrine Provides Update on Status of Cotara Phase III
......"Peregrine FDA have been in close consultation regarding the Cotara Ph3 trial. Peregrine is confident that the Ph3 will adequately address all regulatory, drug safety & efficacy requirements for such a large multi-national trial."
…11-19-02: Peregrine Provides Update on Status of Cotara Phase III
......ELegere: "Although many issues have been finalized, there are several important issues that remain to be negotiated prior to Ph3 approval. We will request an expedited meeting with the FDA so we can clarify & finalize the remaining issues…"
…11-25-02: Peregrine Receives Orphan Drug Designation for Cotara in Europe
…2-24-03: Peregrine Receives FDA Approval for its Cotara Phase III Registration Trial Design for GBM
......"Peregrine has received approval from the FDA to start its Cotara Ph3 registration clinical study in GBM."
TNT3 (Vivatuxin) Lung Cancer Approval/Launch in China:
...Shanghai MediPharm Biotech's TNT/China website:
...8-2010 Profile of Shanghai MediPharm Biotech by WallStreetResearch (Alan Stone):
...3-2010: New Vivatuxin+MicrowaveAblation NSCLC trial (n=2000)
...1-16-07: Medipharm Launches TNT in China for Lung Cancer
...6-19-02: TNT Interim Lung Data from China: &
Peregrine v. CTL Lawsuit - Settled 6-19-09:
...6-19-09: Form 8-K, Peregrine & CTL Settle:
...3-29-07 CTL countersues PPHM over TNT/China licensing dispute:
...3-30-07 PPHM comments on CTL's 3-29-07 countersuit:
...1-12-07: New China Subsidiary; Suit Filed Against Cancer Therapeutics Labs (CTL)
Eur. Licensee Merck-KGaA's TNT/Cytokine Fusion Protein Ph.1 Trial:
...4-3-12: NHS-IL2-LT (EMD 521873) poster at AACR'12
...4-2009: 2nd SELECTIKINE Ph.1 trial added: SELECTIKINE+RAD/NSCLC:
...5-2007: 2nd SELECTIKINE Ph.1 site added, Univ. of Lausanne, Switz:
...Ph.1 Trial Protocol (Merck KGaA/Germany, PI=Dr. R.Stupp):
...2-22-07: TNT-based European Cancer Trial initiated by 'Licensee':
...Clearly, it's Merck-KGaA's 'SELECTIKINE' (NHS-IL2-LT/EMD521873):
...5-1-08 Dr. Missag Parseghian (Dir/R&D) presents VEAs at PEGS/2008:

AFFITECH-PPHM Collab: Fully-Human Mabs, Anti-PS & Anti-VEGF/2C3
• AT001 is Fully-Human 2C3 = R84 = PGN311
• AT004 is Fully-Human BAVI=PGN635=1N11
• AT005 is the Duke-PPHM-HIV candidate PGN632=11.31
4-28-09 Affitech comments on PGN635 & PGN632 presented at AACR'09:
...All Affitech Press Releases:
8-20-12: 1st patient dosed in R84 (AT001) Ph.1 "Various Cancers" Trial in Russia/CIS
3-12-12 Affitech's Board rec's S/H's approve Trans Nova's buyout offer (7.85mm Euros for rem. 60%)
6-16-11: Affitech partners with IBC Generium for R84 dev. in Russia/CIS
…Affitech rec. $2.5mmEURO from IBC; PPHM re-invests $1.6mm payment into "further advancement of R84."
5-26-11 Affitech update on R84 progress: "trial matl. mfg. (by Avid)"
4-28-11: Affitech's Annual SHM (32pg. PDF) - much on R84 progress/plans:
..Affitech's 12-31-10 10-K iss. 4-28-11 - much info on R84 as well:
…$1mm milestone to PPHM for pre-clin-pkg forthcoming? Also, Avid "1st-GMP-Mfg" =>
4-28-11: Affitech signs with UTSW/Dr. Rolf Brekken for further AT001/R84 research:
...Dr. Rolf Brekken's research at UTSW:
2-18-11 Interview with Affitech CEO Dr. Martin Welschof discusses R84 Progress/Plans
Nov/Dec'10: Affitech Reiterates R84 (FH-2C3) Dev. Project Plans
9-30-10: PPHM & Affitech Amend 7-2009 R84 Licensing Agreement
…following Affitech/NTS+ Collab for dev. in Russia/Brazil. Also, Avid gets contract to mfg. R84 for clinical studies.
8-6-10/PLoS: PPHM-Brekken/UTSW/Affitech article on pre-clin. R84=AT001 (Fhu 2C3):
…"Extended r84 therapy controls tumor growth without induction of toxicity"
6-30-10: NTS-Plus to run 2C3/R84 clinical trial(s) in Russia:
…"AT001/r84 differs from Avastin in a number of ways… more selective… may have a better side effect profile."
4-21-10: Affitech sub-licenses Anti-VEGF mabs (incl. R84) to Russian partner NTS-Plus:
11-3-09/PLoS: R.Brekken (PPHM SRB) on R84, increases "immune cell infiltration" in Breast Cancer:
7-22-09: Peregrine Licenses Anti-VEGF mabs (incl. R84) to Affitech:
6-30-09: R.Brekken article in Mol-Cancer-Ther on 2C3/R84+Avastin vs. Breast Cancer:
12-11-08: Dr. Brekken (PPHM SRB) presents F.H. 2C3 (R84/PGN311) at TX Breast-Cancer Conf.
11-3-07: Dr. Brekken presents 'R84' (F.H. 2C3, aka PGN311) data at IBC-Conf:
4-16-07 AACR2007: Brekken [PPHM SRB] presents fully-human 2C3 ('R3')
"The anti-tumor activity of 2C3, which only blocks VEGFR2 compared favorably to that of Avastin, which blocks both VEGFR1+2"
2-14-05: Humanized 2C3 Pre-Clin. data presented at "Anti-Angio. Symposium"
2-10-05: VEGF Pioneer Dr. Donald Senger joins PPHM's SRB to assist with 2C3 pgm:
5-6-12: Dr. Phil Thorpe's poster on PGN632 vs. AMD/CNV at ARVO-2012/FtLaud
1-9-07 PR: VTA Microbubbles as Contrast Agents (AACR/CCR article) &
9-26-06: VTA+Combo Patent Granted; Expands VTA Licensing Opportunities &
8-25-05: PPHM Licenses Conjugated Anti-PSMA VTA Technolody to Medarex:
"These types of deals should add considerable value to the company as our partners move their VTA dev. programs forward."
4-19-05: VEGF121/rGel presented at AACR (50% Survival vs. Prostate Cancer):
###SUPG moving VEGF121/rGel (lic. from PPHM) fwd. via Targa/Rosenblum:
...Rosenblum 11-15-06, "Ph.I human trials of VEGF121/rGel are expected to open shortly at M. D.A."

Thorpe 10-25-04 SHM Presentation: "Understanding Tarvacin", incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities:
"OK, this is Tarvacin.. the cleanest tumor vessel marker of which we are aware.. If you look here at the 3G4 slide, you'll see, most remarkably, that it's absolutely chock full with macrophages; they're beginning to outnumber the tumor cells... . So, the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there; it homes specifically to tumor blood vessels and induces white blood cells to attack the tumor."

Dr. Thorpe's APT (AntiPS/3G4/BAVITUXIMAB patent app #20040161429 (pub. USPO 8-19-04):
"Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids":
[1302] "the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent."
[1303] "...The inhibitory activities of 3G4 on cell division, angiogenesis, tumor growth & viral infectivity, taken together with lack of apparent toxicity, show broad therapeutic indications for this antibody, including in the treatment of angiogenic disorders, cancer, diabetes and viral infections."
[0196] "the anti-viral methods and uses of the invention are suitable for treating all viruses... as exemplified by treating CMV, RSV, arenavirus and HIV infections, and the diseases hepatitis, influenza, pneumonia, Lassa fever and AIDS."
[1298] "The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed."

Thorpe's Aug03-Jan08 $1.68mm NIH/NIAID Grant for research using PPHM's APTs (Anti-PS/3G4) as "Novel Anti-Viral Agents for Treating Lassa Fever":
Thorpe: "We are developing drugs to use against Lassa fever that operate on a new principle in virology. They exploit the fact that viruses coat themselves with an outer membrane where some of the lipids are inside-out. The drugs direct our immune responses to the inside-out components of the viral membrane, or envelope. These drugs potentially could be effective against numerous viruses that have similar outer membranes… We have raised mabs to PS and other anionic phospholipids that block the spread of several viruses to uninfected cells in vitro, essentially completely. The phospholipids that they recognize have the same structure & cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans. The antibodies are not toxic to mice, even when administered in high doses for prolonged periods of time."
GRANT LINK: . . .11-3-03 Grant PR:
###8-26-09: $763k 2yr expansion NIAID grant (8/14/09-7/31/11) to Dr. Thorpe for 2nd-gen. anti-PS/VHF studies:

The Inventor of the PS-Targeting Mabs, like 3G4/bavituximab, is Dr. Philip E. Thorpe of UTSW-MC/Dallas.
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013)
Dr. Thorpe's LAB TEAM (UTSW Hamon Center):
…2013: Dr. Thorpe’s lab taken over by UTSW’s Dr. Rolf A. Brekken:
Dr. Thorpe's Patents: GRANTED: PENDING:
…Dr. Thorpe's Articles: Also see:
Dr. Brekken’s Patents: GRANTED: PENDING:
…Dr. Brekken’s Articles: Also see:
Dr. Alan Schroit's Patents (MDA, PPHM SRB, “Clipped B2GP1”): GRANTED: PENDING:  
…Dr. Schroit’s Articles: Also see: (UTSW profile)

PPHM BOARD RULES:  - DISCLAIMER: This msg board is not affiliated with Peregrine; no endorsement by Peregrine or any other org. is implied.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PPHM News: Amended Statement of Beneficial Ownership (sc 13d/a) 06/20/2017 05:27:00 PM
PPHM News: Current Report Filing (8-k) 06/07/2017 04:33:15 PM
PPHM News: Current Report Filing (8-k) 06/06/2017 04:26:06 PM
PPHM News: Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock 06/06/2017 04:05:00 PM
PPHM News: Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017 06/05/2017 08:05:00 AM
#300379  Sticky Note PPHM’s Exosomes Diag. Platform (incl. 6-22-2017 NATURE/BJC article) cjgaddy 06/23/17 12:34:43 PM
#298792  Sticky Note Sunrise Biomarkers (#1/B2GPI #2/COMPL,IL10 #3/IFN-y #4/PD-L1) – updated cjgaddy 06/06/17 12:10:40 PM
#297406  Sticky Note Known Upcoming Events (incl. ASCO’17: Analysis/Sunrise PD-L1 Expression) cjgaddy 05/19/17 03:09:38 PM
#294957  Sticky Note PPHM/MSKCC(Jedd Wolchok Lab) Collab: #1/Bavi+PD1+Rad, #2/Bavi+”ACT” cjgaddy 04/14/17 10:05:54 AM
#290976  Sticky Note 3-13-17 Qtly CC-Transcript, PR(Financials Q3FY17/qe1-31-17), updated Avid Revenues cjgaddy 03/14/17 03:41:25 PM
#287840  Sticky Note Collabs with Mem.Sloan(Wolchok), Duke, MDA, Rutgers, ImmunoVaccine, UTSW… cjgaddy 02/28/17 12:25:52 PM
#300848   What exactly are you winning in? I'm long and spankyvol 06/29/17 06:00:02 AM
#300847   I´m not quite sure but I think Bavituximab/Peregrine hutschi 06/29/17 05:53:27 AM
#300846   The host-cell restriction factor SERINC5 restricts HIV-1 infectivity hutschi 06/29/17 05:42:56 AM
#300845   Ona Yahoo-Board: Just an his/her opinion! hutschi 06/29/17 04:33:43 AM
#300844   Hutchison China Meditech Limited - Chi-Med and AstraZeneca hutschi 06/29/17 03:49:53 AM
#300843   Loof, the picture in you msg says it all. ku 06/29/17 01:02:37 AM
#300842   So what did this long msg say?? ku 06/29/17 12:59:17 AM
#300841   You are correct, I should have been less TampaTradr 06/29/17 12:41:50 AM
#300840   You are absolutely not alone! Long INVESTORS outnumber eb0783 06/29/17 12:38:48 AM
#300839   Thank you I'm glad im.not alone Bluerinse 06/29/17 12:26:38 AM
#300838   A perfect calm sets in ...despite the endless sulaco 06/28/17 11:05:48 PM
#300837   New this year! biopharm 06/28/17 11:00:44 PM
#300836   KT, one out of four PSA tests showing sulaco 06/28/17 10:37:24 PM
#300835   TT, I have one and you're right. ArchieK 06/28/17 09:32:58 PM
#300834   Understand and appreciate your response. goodplenty100 06/28/17 08:42:24 PM
#300833   The host-cell restriction factor SERINC5 restricts HIV-1 infectivity biopharm 06/28/17 08:24:32 PM
#300832   I am not nearly as knowledgeable about PPHM TampaTradr 06/28/17 08:24:23 PM
#300831   Interested in your thoughts on this TT goodplenty100 06/28/17 07:55:54 PM
#300830   I have personal experience with kidney cysts. The TampaTradr 06/28/17 07:51:15 PM
#300829   I don't know what's not true, if you Bamboozler762 06/28/17 07:44:08 PM
#300828   the bird is cooked Gwen. revenue_monster 06/28/17 07:24:49 PM
#300827   Not true TampaTradr 06/28/17 07:11:34 PM
#300826   A perfect calm sets in ...despite the endless Bluerinse 06/28/17 07:10:26 PM
#300825   Again, the sabotage theory. If they had the TampaTradr 06/28/17 07:04:49 PM
#300824   They want a reverse split. corporalagarn 06/28/17 06:59:53 PM
#300822   The share price will decline without near term 2ndstr2thert 06/28/17 06:38:52 PM
#300821   Less liquidity. In turn, the BOD would not The Other Guy 06/28/17 06:23:20 PM
#300820   On a somewhat related note, I spoke with Bamboozler762 06/28/17 06:17:24 PM
#300819   My sentiments exactly. Can anyone give a reason(s) 2ndstr2thert 06/28/17 06:14:29 PM
#300818   The bird seems to be flopping rather than flapping. cheynew 06/28/17 06:14:08 PM
#300817   Betcha a steak dinner they found the new biopharm 06/28/17 06:10:22 PM
#300815   I believe they would had have to file geocappy1 06/28/17 05:14:22 PM
#300814   Sulaco, there is a lot going on so keep_trying 06/28/17 05:07:48 PM
#300813   The new PPHM theme song........? patientlywaiting 06/28/17 05:04:43 PM
#300812   The patents are very secure? asmarterwookie 06/28/17 04:36:56 PM
#300811   that they are as stupid as the rest revenue_monster 06/28/17 04:30:48 PM
#300810   You're welcome. asmarterwookie 06/28/17 04:27:28 PM
#300809   Does the big money coming in to this goldfinger 06/28/17 04:24:49 PM
#300808   Your comments are the first of very few TekNuLoof 06/28/17 04:23:10 PM
#300807   Answer or excuse? The Other Guy 06/28/17 04:12:46 PM
#300806   That's been the answer for ten years. corporalagarn 06/28/17 04:11:08 PM
#300804 al... asmarterwookie 06/28/17 04:01:17 PM
#300803 be clear. I am talking g about asmarterwookie 06/28/17 03:42:59 PM
#300802   The easy answer is you can't have insiders eastcoastguy 06/28/17 03:33:19 PM
#300801   as in imminent? revenue_monster 06/28/17 03:30:50 PM
#300799   Golfho, re your response to Wook below: JamesGMS 06/28/17 03:25:17 PM
#300796 all steps were executed exactly as outlined golfho 06/28/17 02:48:43 PM
#300792   Golfho, you forgot this part: corporalagarn 06/28/17 02:25:21 PM
#300791 all steps were executed exactly as outlined asmarterwookie 06/28/17 02:18:46 PM
#300789   "Why is that well said?" patientlywaiting 06/28/17 02:10:28 PM